{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:05:34Z","timestamp":1792839934670,"version":"4.5.0"},"reference-count":408,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche Diagnostics International","id":[{"id":"https:\/\/ror.org\/02s7j3326","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00401-018-1932-x","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T02:38:02Z","timestamp":1543372682000},"page":"821-853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":486,"title":["Current state of Alzheimer\u2019s fluid biomarkers"],"prefix":"10.1007","volume":"136","author":[{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Ayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Batrla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Bednar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvydas","family":"Mikulskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sid","family":"O\u2019Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sevigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly D.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"1932_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/00365513.2017.1335880","volume":"77","author":"L Agnello","year":"2017","unstructured":"Agnello L, Bivona G, Novo G, Scazzone C, Muratore R, Levantino P et al (2017) Heart-type fatty acid binding protein is a sensitive biomarker for early AMI detection in troponin negative patients: a pilot study. Scand J Clin Lab Invest 77:428\u2013432. https:\/\/doi.org\/10.1080\/00365513.2017.1335880","journal-title":"Scand J Clin Lab Invest"},{"key":"1932_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/wnl.0000000000001859","volume":"85","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, Mart\u00ednez-Lage P, S\u00e1nchez-Juan P, Olaz\u00e1ran J, Ant\u00fanez C, Izagirre A et al (2015) Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 85:626\u2013633. https:\/\/doi.org\/10.1212\/wnl.0000000000001859","journal-title":"Neurology"},{"key":"1932_CR3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.neurobiolaging.2015.03.001","volume":"36","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, Vilaplana E, Pegueroles J, Montal V, S\u00e1nchez-Juan P, Gonz\u00e1lez-Su\u00e1rez A et al (2015) Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer\u2019s disease. Neurobiol Aging 36:2018\u20132023. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.03.001","journal-title":"Neurobiol Aging"},{"key":"1932_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/WNL.0000000000004088","volume":"89","author":"D Alcolea","year":"2017","unstructured":"Alcolea D, Vilaplana E, Su\u00e1rez-Calvet M, Ill\u00e1n-Gala I, Blesa R, Clarim\u00f3n J et al (2017) CSF sAPP\u03b2, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology 89:178\u2013188. https:\/\/doi.org\/10.1212\/WNL.0000000000004088","journal-title":"Neurology"},{"key":"1932_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13195-016-0220-z","volume":"8","author":"P Alexopoulos","year":"2016","unstructured":"Alexopoulos P, Werle L, Roesler J, Thierjung N, Gleixner LS, Yakushev I et al (2016) Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer\u2019s disease. Alzheimers Res Ther 8:51. https:\/\/doi.org\/10.1186\/s13195-016-0220-z","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","volume":"12","author":"Alzheimer\u2019s Association","year":"2016","unstructured":"Association Alzheimer\u2019s (2016) Alzheimer\u2019s disease facts and figures. Alzheimers Dement 12:459\u2013509","journal-title":"Alzheimers Dement"},{"key":"1932_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ana.21154","volume":"61","author":"C Amador-Ortiz","year":"2007","unstructured":"Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer\u2019s disease. Ann Neurol 61:435\u2013445. https:\/\/doi.org\/10.1002\/ana.21154","journal-title":"Ann Neurol"},{"key":"1932_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JAD-170035","volume":"59","author":"S Anand","year":"2017","unstructured":"Anand S, Barnes JM, Young SA, Garcia DM, Tolley HD, Kauwe JSK et al (2017) Discovery and confirmation of diagnostic serum lipid biomarkers for Alzheimer\u2019s disease using direct infusion mass spectrometry. J Alzheimers Dis 59:277\u2013290. https:\/\/doi.org\/10.3233\/JAD-170035","journal-title":"J Alzheimers Dis"},{"key":"1932_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0304-3940(99)00617-5","volume":"273","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B et al (1999) Cerebrospinal fluid tau and A\u03b242 as predictors of development of Alzheimer\u2019s disease in patients with mild cognitive impairment. Neurosci Lett 273:5\u20138","journal-title":"Neurosci Lett"},{"key":"1932_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1084\/jem.182.1.155","volume":"182","author":"AL Angiolillo","year":"1995","unstructured":"Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S et al (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182:155\u2013162","journal-title":"J Exp Med"},{"key":"1932_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/jad-140624","volume":"42","author":"A Antonell","year":"2014","unstructured":"Antonell A, Mansilla A, Rami L, Llad\u00f3 A, Iranzo A, Olives J et al (2014) Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer\u2019s disease. J Alzheimers Dis 42:901\u2013908. https:\/\/doi.org\/10.3233\/jad-140624","journal-title":"J Alzheimers Dis"},{"key":"1932_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/JAD-160573","volume":"55","author":"SP Arneri\u0107","year":"2017","unstructured":"Arneri\u0107 SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L et al (2017) Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: a view of the regulatory science qualification landscape from the Coalition Against Major Diseases CSF Biomarker Team. J Alzheimers Dis 55:19\u201335. https:\/\/doi.org\/10.3233\/JAD-160573","journal-title":"J Alzheimers Dis"},{"key":"1932_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/jnnp-2017-316551","volume":"89","author":"S Ayton","year":"2017","unstructured":"Ayton S, Diouf I, Bush AI, Alzheimer\u2019s Disease Neuroimaging Initiative (2017) Evidence that iron accelerates Alzheimer\u2019s pathology: a CSF biomarker study. J Neurol Neurosurg Psychiatry 89:456\u2013460. https:\/\/doi.org\/10.1136\/jnnp-2017-316551","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1932_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1001\/jamaneurol.2016.4406","volume":"74","author":"S Ayton","year":"2017","unstructured":"Ayton S, Faux NG, Bush AI (2017) Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-\u025b4 carriers. JAMA Neurol 74:122\u2013125. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4406","journal-title":"JAMA Neurol"},{"key":"1932_CR15","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1038\/ncomms7760","volume":"6","author":"S Ayton","year":"2015","unstructured":"Ayton S, Faux NG, Bush AI, Alzheimer\u2019s Disease Neuroimaging Initiative (2015) Ferritin levels in the cerebrospinal fluid predict Alzheimer\u2019s disease outcomes and are regulated by APOE. Nat Commun 6:6760. https:\/\/doi.org\/10.1038\/ncomms7760","journal-title":"Nat Commun"},{"key":"1932_CR16","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/brain\/awx137","volume":"140","author":"S Ayton","year":"2017","unstructured":"Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY et al (2017) Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline. Brain 140:2112\u20132119. https:\/\/doi.org\/10.1093\/brain\/awx137","journal-title":"Brain"},{"key":"1932_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3233\/jad-150705","volume":"50","author":"M Babi\u0107 Leko","year":"2016","unstructured":"Babi\u0107 Leko M, Borove\u010dki F, Dejanovi\u0107 N, Hof PR, \u015cimi\u0107 G (2016) Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer\u2019s disease early detection and differential diagnosis in patients with mild cognitive impairment. J Alzheimers Dis 50:765\u2013778. https:\/\/doi.org\/10.3233\/jad-150705","journal-title":"J Alzheimers Dis"},{"key":"1932_CR18","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/med.21434","volume":"37","author":"SO Bachurin","year":"2017","unstructured":"Bachurin SO, Bovina EV, Ustyugov AA (2017) Drugs in clinical trials for Alzheimer\u2019s disease: the major trends. Med Res Rev 37:1186\u20131225. https:\/\/doi.org\/10.1002\/med.21434","journal-title":"Med Res Rev"},{"key":"1932_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40265-015-0529-0","volume":"76","author":"L Bakota","year":"2016","unstructured":"Bakota L, Brandt R (2016) Tau biology and tau-directed therapies for Alzheimer\u2019s disease. Drugs 76:301\u2013313. https:\/\/doi.org\/10.1007\/s40265-015-0529-0","journal-title":"Drugs"},{"key":"1932_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","volume":"14","author":"F Baldacci","year":"2017","unstructured":"Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H (2017) Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer\u2019s disease and other neurodegenerative diseases. Expert Rev Proteom 14:285\u2013299. https:\/\/doi.org\/10.1080\/14789450.2017.1304217","journal-title":"Expert Rev Proteom"},{"key":"1932_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jshs.2016.08.007","volume":"5","author":"F Baldacci","year":"2016","unstructured":"Baldacci F, Lista S, Garaci F, Bonuccelli U, Toschi N, Hampel H (2016) Biomarker-guided classification scheme of neurodegenerative diseases. J Sport Health Sci 5:383\u2013387","journal-title":"J Sport Health Sci"},{"key":"1932_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-1-4939-7704-8_9","volume":"1750","author":"F Baldacci","year":"2018","unstructured":"Baldacci F, Lista S, O\u2019Bryant SE, Ceravolo R, Toschi N, Hampel H et al (2018) Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases. Methods Mol Biol 1750:139\u2013155. https:\/\/doi.org\/10.1007\/978-1-4939-7704-8_9","journal-title":"Methods Mol Biol"},{"key":"1932_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jalz.2017.01.021","volume":"13","author":"F Baldacci","year":"2017","unstructured":"Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I et al (2017) Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer\u2019s disease. Alzheimers Dement 13:993\u20131003. https:\/\/doi.org\/10.1016\/j.jalz.2017.01.021","journal-title":"Alzheimers Dement"},{"key":"1932_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/acschemneuro.6b00384","volume":"8","author":"C Ballatore","year":"2017","unstructured":"Ballatore C, Brunden KR, Trojanowski JQ, Lee VM, Smith AB 3rd (2017) Non-naturally occurring small molecule microtubule-stabilizing agents: a potential tactic for CNS-directed therapies. ACS Chem Neurosci 8:5\u20137. https:\/\/doi.org\/10.1021\/acschemneuro.6b00384","journal-title":"ACS Chem Neurosci"},{"key":"1932_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00401-014-1287-x","volume":"127","author":"TA Bayer","year":"2014","unstructured":"Bayer TA, Wirths O (2014) Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer\u2019s disease. Acta Neuropathol 127:787\u2013801. https:\/\/doi.org\/10.1007\/s00401-014-1287-x","journal-title":"Acta Neuropathol"},{"key":"1932_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jprot.2018.04.027","volume":"182","author":"I Begcevic","year":"2018","unstructured":"Begcevic I, Brinc D, Brown M, Martinez-Morillo E, Goldhardt O, Grimmer T et al (2018) Brain-related proteins as potential CSF biomarkers of Alzheimer\u2019s disease: a targeted mass spectrometry approach. J Proteom 182:12\u201320. https:\/\/doi.org\/10.1016\/j.jprot.2018.04.027","journal-title":"J Proteom"},{"key":"1932_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12883-016-0706-0","volume":"16","author":"G Berge","year":"2016","unstructured":"Berge G, Sando SB, Albrektsen G, Lauridsen C, M\u00f8ller I, Gr\u00f8ntvedt GR et al (2016) Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer\u2019s disease, mild cognitive impairment, or healthy controls: a two year follow-up study. BMC Neurol 16:180. https:\/\/doi.org\/10.1186\/s12883-016-0706-0","journal-title":"BMC Neurol"},{"key":"1932_CR28","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1212\/NXI.0000000000000271","volume":"3","author":"J Bergman","year":"2016","unstructured":"Bergman J, Dring A, Zetterberg H, Blennow K, Norgren N, Gilthorpe J et al (2016) Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm 3:e271. https:\/\/doi.org\/10.1212\/NXI.0000000000000271","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1932_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-170602","volume":"62","author":"BM Bettcher","year":"2018","unstructured":"Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S et al (2018) Cerebrospinal fluid and plasma levels of inflammation differentially relate to CNS markers of Alzheimer\u2019s disease pathology and neuronal damage. J Alzheimers Dis 62:385\u2013397. https:\/\/doi.org\/10.3233\/JAD-170602","journal-title":"J Alzheimers Dis"},{"key":"1932_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/BF01273157","volume":"103","author":"K Blennow","year":"1996","unstructured":"Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P (1996) Synaptic pathology in Alzheimer\u2019s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm (Vienna) 103:603\u2013618. https:\/\/doi.org\/10.1007\/BF01273157","journal-title":"J Neural Transm (Vienna)"},{"key":"1932_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12603-009-0059-0","volume":"13","author":"K Blennow","year":"2009","unstructured":"Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H et al (2009) Evolution of Abeta42 and Abeta40 levels and Abeta42\/Abeta40 ratio in plasma during progression of Alzheimer\u2019s disease: a multicenter assessment. J Nutr Health Aging 13:205\u2013208","journal-title":"J Nutr Health Aging"},{"key":"1932_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","volume":"11","author":"K Blennow","year":"2015","unstructured":"Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease. Alzheimers Dement 11:58\u201369. https:\/\/doi.org\/10.1016\/j.jalz.2014.02.004","journal-title":"Alzheimers Dement"},{"key":"1932_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131\u2013144. https:\/\/doi.org\/10.1038\/nrneurol.2010.4","journal-title":"Nat Rev Neurol"},{"key":"1932_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neulet.2007.03.064","volume":"419","author":"K Blennow","year":"2007","unstructured":"Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P et al (2007) Longitudinal stability of CSF biomarkers in Alzheimer\u2019s disease. Neurosci Lett 419:18\u201322. https:\/\/doi.org\/10.1016\/j.neulet.2007.03.064","journal-title":"Neurosci Lett"},{"key":"1932_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrn3887","volume":"16","author":"J Brettschneider","year":"2015","unstructured":"Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ (2015) Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 16:109\u2013120. https:\/\/doi.org\/10.1038\/nrn3887","journal-title":"Nat Rev Neurosci"},{"key":"1932_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, Brinkmalm G, Honer WG, Fr\u00f6lich L, Hausner L, Minthon L et al (2014) SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener 9:53. https:\/\/doi.org\/10.1186\/1750-1326-9-53","journal-title":"Mol Neurodegener"},{"key":"1932_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/JIR.S86958","volume":"9","author":"MR Bronzuoli","year":"2016","unstructured":"Bronzuoli MR, Iacomino A, Steardo L, Scuderi C (2016) Targeting neuroinflammation in Alzheimer\u2019s disease. J Inflamm Res 9:199\u2013208. https:\/\/doi.org\/10.2147\/JIR.S86958","journal-title":"J Inflamm Res"},{"key":"1932_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-018-0353-3","volume":"10","author":"F Brosseron","year":"2018","unstructured":"Brosseron F, Traschutz A, Widmann CN, Kummer MP, Tacik P, Santarelli F et al (2018) Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer\u2019s disease. Alzheimers Res Ther 10:25. https:\/\/doi.org\/10.1186\/s13195-018-0353-3","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR39","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.2174\/15672050113106660168","volume":"10","author":"KA Bruggink","year":"2013","unstructured":"Bruggink KA, Kuiperij HB, Claassen JA, Verbeek MM (2013) The diagnostic value of CSF amyloid-beta(43) in differentiation of dementia syndromes. Curr Alzheimer Res 10:1034\u20131040","journal-title":"Curr Alzheimer Res"},{"key":"1932_CR40","doi-asserted-by":"publisher","first-page":"13861","DOI":"10.1523\/jneurosci.3059-10.2010","volume":"30","author":"KR Brunden","year":"2010","unstructured":"Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM et al (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 30:13861\u201313866. https:\/\/doi.org\/10.1523\/jneurosci.3059-10.2010","journal-title":"J Neurosci"},{"key":"1932_CR41","doi-asserted-by":"publisher","first-page":"e6294","DOI":"10.1371\/journal.pone.0006294","volume":"4","author":"P Buchhave","year":"2009","unstructured":"Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L et al (2009) Longitudinal study of CSF biomarkers in patients with Alzheimer\u2019s disease. PLoS One 4:e6294. https:\/\/doi.org\/10.1371\/journal.pone.0006294","journal-title":"PLoS One"},{"key":"1932_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.14283\/jpad.2017.39","volume":"4","author":"S Budd Haeberlein","year":"2017","unstructured":"Budd Haeberlein S, O\u2019Gorman J, Chiao P, Bussiere T, von Rosenstiel P, Tian Y et al (2017) Clinical development of aducanumab, an anti-Abeta human monoclonal antibody being investigated for the treatment of early Alzheimer\u2019s disease. J Prev Alzheimers Dis 4:255\u2013263. https:\/\/doi.org\/10.14283\/jpad.2017.39","journal-title":"J Prev Alzheimers Dis"},{"key":"1932_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/s1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol 16:601\u2013609. https:\/\/doi.org\/10.1016\/s1474-4422(17)30124-2","journal-title":"Lancet Neurol"},{"key":"1932_CR44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement 12:719\u2013732. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.010","journal-title":"Alzheimers Dement"},{"key":"1932_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.brainresbull.2016.04.019","volume":"126","author":"CM Carroll","year":"2016","unstructured":"Carroll CM, Li YM (2016) Physiological and pathological roles of the \u03b3-secretase complex. Brain Res Bull 126:199\u2013206. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.04.019","journal-title":"Brain Res Bull"},{"key":"1932_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-7704-8_3","volume":"1750","author":"JI Castrillo","year":"2018","unstructured":"Castrillo JI, Lista S, Hampel H, Ritchie CW (2018) Systems biology methods for Alzheimer\u2019s disease research toward molecular signatures, subtypes, and stages and precision medicine: application in cohort studies and trials. Methods Mol Biol 1750:31\u201366. https:\/\/doi.org\/10.1007\/978-1-4939-7704-8_3","journal-title":"Methods Mol Biol"},{"key":"1932_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2174\/1567205013666160620111408","volume":"14","author":"AM Catafau","year":"2017","unstructured":"Catafau AM, Bullich S (2017) Non-amyloid PET imaging biomarkers for neurodegeneration: focus on tau, alpha-synuclein and neuroinflammation. Curr Alzheimer Res 14:169\u2013177","journal-title":"Curr Alzheimer Res"},{"key":"1932_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.vph.2016.11.008","volume":"89","author":"A Chakraborty","year":"2017","unstructured":"Chakraborty A, de Wit NM, van der Flier WM, de Vries HE (2017) The blood brain barrier in Alzheimer\u2019s disease. Vascul Pharmacol 89:12\u201318. https:\/\/doi.org\/10.1016\/j.vph.2016.11.008","journal-title":"Vascul Pharmacol"},{"key":"1932_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2016.04.012","volume":"97","author":"KA Chang","year":"2016","unstructured":"Chang KA, Shin KY, Nam E, Lee YB, Moon C, Suh YH et al (2016) Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer\u2019s disease. Neurochem Int 97:1\u20137. https:\/\/doi.org\/10.1016\/j.neuint.2016.04.012","journal-title":"Neurochem Int"},{"key":"1932_CR50","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1007\/s12035-015-9264-5","volume":"53","author":"XL Chang","year":"2016","unstructured":"Chang XL, Tan MS, Tan L, Yu JT (2016) The role of TDP-43 in Alzheimer\u2019s disease. Mol Neurobiol 53:3349\u20133359. https:\/\/doi.org\/10.1007\/s12035-015-9264-5","journal-title":"Mol Neurobiol"},{"key":"1932_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrneurol.2010.18","volume":"6","author":"AS Chen-Plotkin","year":"2010","unstructured":"Chen-Plotkin AS, Lee VM, Trojanowski JQ (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 6:211\u2013220. https:\/\/doi.org\/10.1038\/nrneurol.2010.18","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 1","key":"1932_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jnc.13062","volume":"136","author":"Z Chen","year":"2016","unstructured":"Chen Z, Trapp BD (2016) Microglia and neuroprotection. J Neurochem 136(Suppl 1):10\u201317. https:\/\/doi.org\/10.1111\/jnc.13062","journal-title":"J Neurochem"},{"key":"1932_CR53","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13195-017-0276-4","volume":"9","author":"D Chiasserini","year":"2017","unstructured":"Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S et al (2017) Differential role of CSF fatty acid binding protein 3, \u03b1-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia. Alzheimers Res Ther 9:52. https:\/\/doi.org\/10.1186\/s13195-017-0276-4","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR54","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00415-011-6087-9","volume":"258","author":"J Choi","year":"2011","unstructured":"Choi J, Lee HW, Suk K (2011) Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer\u2019s disease. J Neurol 258:2181\u20132185. https:\/\/doi.org\/10.1007\/s00415-011-6087-9","journal-title":"J Neurol"},{"key":"1932_CR55","first-page":"339","volume":"19","author":"CR Cornett","year":"1998","unstructured":"Cornett CR, Markesbery WR, Ehmann WD (1998) Imbalances of trace elements related to oxidative damage in Alzheimer\u2019s disease brain. Neurotoxicology 19:339\u2013345","journal-title":"Neurotoxicology"},{"key":"1932_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000466688","volume":"7","author":"G Corso","year":"2017","unstructured":"Corso G, Cristofano A, Sapere N, la Marca G, Angiolillo A, Vitale M et al (2017) Serum amino acid profiles in normal subjects and in patients with or at risk of Alzheimer dementia. Dement Geriatr Cogn Dis Extra 7:143\u2013159. https:\/\/doi.org\/10.1159\/000466688","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"1932_CR57","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ et al (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry 68:903\u2013912. https:\/\/doi.org\/10.1016\/j.biopsych.2010.08.025","journal-title":"Biol Psychiatry"},{"key":"1932_CR58","doi-asserted-by":"publisher","first-page":"9812178","DOI":"10.1155\/2016\/9812178","volume":"2016","author":"JS Crist\u00f3v\u00e3o","year":"2016","unstructured":"Crist\u00f3v\u00e3o JS, Santos R, Gomes CM (2016) Metals and neuronal metal binding proteins implicated in Alzheimer\u2019s disease. Oxid Med Cell Longev 2016:9812178. https:\/\/doi.org\/10.1155\/2016\/9812178","journal-title":"Oxid Med Cell Longev"},{"key":"1932_CR59","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuron.2013.02.026","volume":"78","author":"C Cruchaga","year":"2013","unstructured":"Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM et al (2013) GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer\u2019s disease. Neuron 78:256\u2013268. https:\/\/doi.org\/10.1016\/j.neuron.2013.02.026","journal-title":"Neuron"},{"key":"1932_CR60","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","volume":"3","author":"J Cummings","year":"2017","unstructured":"Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K (2017) Alzheimer\u2019s disease drug development pipeline: 2017. Alzheimers Dement (N Y) 3:367\u2013384. https:\/\/doi.org\/10.1016\/j.trci.2017.05.002","journal-title":"Alzheimers Dement (N Y)"},{"key":"1932_CR61","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jalz.2016.06.001","volume":"12","author":"JL Dage","year":"2016","unstructured":"Dage JL, Wennberg AM, Airey DC, Hagen CE, Knopman DS, Machulda MM et al (2016) Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement 12:1226\u20131234. https:\/\/doi.org\/10.1016\/j.jalz.2016.06.001","journal-title":"Alzheimers Dement"},{"key":"1932_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1017\/S1041610298005110","volume":"10","author":"P Davidsson","year":"1998","unstructured":"Davidsson P, Blennow K (1998) Neurochemical dissection of synaptic pathology in Alzheimer\u2019s disease. Int Psychogeriatr 10:11\u201323","journal-title":"Int Psychogeriatr"},{"key":"1932_CR63","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","volume":"11","author":"A Vos De","year":"2015","unstructured":"De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E et al (2015) C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease. Alzheimers Dement 11:1461\u20131469. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.012","journal-title":"Alzheimers Dement"},{"key":"1932_CR64","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3233\/jad-160227","volume":"53","author":"A Vos De","year":"2016","unstructured":"De Vos A, Struyfs H, Jacobs D, Fransen E, Klewansky T, De Roeck E et al (2016) The cerebrospinal fluid neurogranin\/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer\u2019s disease. J Alzheimers Dis 53:1523\u20131538. https:\/\/doi.org\/10.3233\/jad-160227","journal-title":"J Alzheimers Dis"},{"key":"1932_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-016-0191-0","volume":"8","author":"M Degerman Gunnarsson","year":"2016","unstructured":"Degerman Gunnarsson M, Ingelsson M, Blennow K, Basun H, Lannfelt L, Kilander L (2016) High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer\u2019s disease. Alzheimers Res Ther 8:22. https:\/\/doi.org\/10.1186\/s13195-016-0191-0","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR66","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/mds.27001","volume":"32","author":"M Delgado-Alvarado","year":"2017","unstructured":"Delgado-Alvarado M, Gago B, Gorostidi A, Jim\u00e9nez-Urbieta H, Dacosta-Aguayo R, Navalpotro-G\u00f3mez I et al (2017) Tau\/alpha-synuclein ratio and inflammatory proteins in Parkinson\u2019s disease: an exploratory study. Mov Disord 32:1066\u20131073. https:\/\/doi.org\/10.1002\/mds.27001","journal-title":"Mov Disord"},{"key":"1932_CR67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-8-39","volume":"8","author":"RS Desikan","year":"2013","unstructured":"Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H et al (2013) Heart fatty acid binding protein and A\u03b2-associated Alzheimer\u2019s neurodegeneration. Mol Neurodegener 8:39. https:\/\/doi.org\/10.1186\/1750-1326-8-39","journal-title":"Mol Neurodegener"},{"key":"1932_CR68","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3233\/JAD-161114","volume":"58","author":"KD Deters","year":"2017","unstructured":"Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K et al (2017) Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis 58:1245\u20131254. https:\/\/doi.org\/10.3233\/JAD-161114","journal-title":"J Alzheimers Dis"},{"key":"1932_CR69","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nbd.2015.08.014","volume":"82","author":"LY Marco Di","year":"2015","unstructured":"Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF (2015) Vascular dysfunction in the pathogenesis of Alzheimer\u2019s disease\u2014a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis 82:593\u2013606. https:\/\/doi.org\/10.1016\/j.nbd.2015.08.014","journal-title":"Neurobiol Dis"},{"key":"1932_CR70","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/iub.357","volume":"62","author":"FJ D\u00edez-Guerra","year":"2010","unstructured":"D\u00edez-Guerra FJ (2010) Neurogranin, a link between calcium\/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 62:597\u2013606. https:\/\/doi.org\/10.1002\/iub.357","journal-title":"IUBMB Life"},{"key":"1932_CR71","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A et al (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81:857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954","journal-title":"Ann Neurol"},{"key":"1932_CR72","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370:311\u2013321. https:\/\/doi.org\/10.1056\/NEJMoa1312889","journal-title":"N Engl J Med"},{"key":"1932_CR73","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fneur.2015.00247","volume":"6","author":"A Dorey","year":"2015","unstructured":"Dorey A, Perret-Liaudet A, Tholance Y, Fourier A, Quadrio I (2015) Cerebrospinal fluid A\u03b240 improves the interpretation of A\u03b242 concentration for diagnosing Alzheimer\u2019s disease. Front Neurol 6:247. https:\/\/doi.org\/10.3389\/fneur.2015.00247","journal-title":"Front Neurol"},{"key":"1932_CR74","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2990.2007.00899.x","volume":"34","author":"EC Downes","year":"2008","unstructured":"Downes EC, Robson J, Grailly E, Abdel-All Z, Xuereb J, Brayne C et al (2008) Loss of synaptophysin and synaptosomal-associated protein 25-kDa (SNAP-25) in elderly down syndrome individuals. Neuropathol Appl Neurobiol 34:12\u201322. https:\/\/doi.org\/10.1111\/j.1365-2990.2007.00899.x","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1932_CR75","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/s1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol 13:614\u2013629. https:\/\/doi.org\/10.1016\/s1474-4422(14)70090-0","journal-title":"Lancet Neurol"},{"key":"1932_CR76","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M et al (2017) Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst) 8:111\u2013126. https:\/\/doi.org\/10.1016\/j.dadm.2017.04.007","journal-title":"Alzheimers Dement (Amst)"},{"key":"1932_CR77","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (2011) Qualification opinion of Alzheimer\u2019s disease novel methodologies\/biomarkers for the use of CSF amyloid beta 1-42 and t-tau signature and\/or PET-amyloid imaging (positive\/negative) as biomarkers for enrichment, for use in regulatory clinical trials in mild and moderate Alzheimer\u2019s disease. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2011\/12\/WC500118365.pdf"},{"key":"1932_CR78","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (2018) Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2018\/02\/WC500244609.pdf"},{"key":"1932_CR79","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/jad-2011-091153","volume":"25","author":"M Ewers","year":"2011","unstructured":"Ewers M, Cheng X, Zhong Z, Nural HF, Walsh C, Meindl T et al (2011) Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer\u2019s disease. J Alzheimers Dis 25:373\u2013381. https:\/\/doi.org\/10.3233\/jad-2011-091153","journal-title":"J Alzheimers Dis"},{"key":"1932_CR80","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.jalz.2014.12.006","volume":"11","author":"M Ewers","year":"2015","unstructured":"Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J et al (2015) CSF biomarkers for the differential diagnosis of Alzheimer\u2019s disease: a large-scale international multicenter study. Alzheimers Dement 11:1306\u20131315. https:\/\/doi.org\/10.1016\/j.jalz.2014.12.006","journal-title":"Alzheimers Dement"},{"key":"1932_CR81","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/awn034","volume":"131","author":"M Ewers","year":"2008","unstructured":"Ewers M, Zhong Z, B\u00fcrger K, Wallin A, Blennow K, Teipel SJ et al (2008) Increased CSF-BACE 1 activity is associated with ApoE-\u03b54 genotype in subjects with mild cognitive impairment and Alzheimer\u2019s disease. Brain 131:1252\u20131258. https:\/\/doi.org\/10.1093\/brain\/awn034","journal-title":"Brain"},{"key":"1932_CR82","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann Neurol 59:512\u2013519. https:\/\/doi.org\/10.1002\/ana.20730","journal-title":"Ann Neurol"},{"key":"1932_CR83","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med 1:371\u2013380. https:\/\/doi.org\/10.1002\/emmm.200900048","journal-title":"EMBO Mol Med"},{"key":"1932_CR84","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau\/\u03b2-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343\u2013349. https:\/\/doi.org\/10.1001\/archneur.64.3.noc60123","journal-title":"Arch Neurol"},{"key":"1932_CR85","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archneurol.2011.105","volume":"68","author":"AM Fagan","year":"2011","unstructured":"Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ et al (2011) Comparison of analytical platforms for cerebrospinal fluid measures of \u03b2-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 68:1137\u20131144. https:\/\/doi.org\/10.1001\/archneurol.2011.105","journal-title":"Arch Neurol"},{"key":"1932_CR86","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S et al (2016) Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3:812\u2013818. https:\/\/doi.org\/10.1002\/acn3.338","journal-title":"Ann Clin Transl Neurol"},{"key":"1932_CR87","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","volume":"8","author":"N Fandos","year":"2017","unstructured":"Fandos N, P\u00e9rez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL et al (2017) Plasma amyloid \u03b2 42\/40 ratios as biomarkers for amyloid \u03b2 cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) 8:179\u2013187. https:\/\/doi.org\/10.1016\/j.dadm.2017.07.004","journal-title":"Alzheimers Dement (Amst)"},{"key":"1932_CR88","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","volume":"8","author":"M Farlow","year":"2012","unstructured":"Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP et al (2012) Safety and biomarker effects of solanezumab in patients with Alzheimer\u2019s disease. Alzheimers Dement 8:261\u2013271. https:\/\/doi.org\/10.1016\/j.jalz.2011.09.224","journal-title":"Alzheimers Dement"},{"key":"1932_CR89","doi-asserted-by":"publisher","first-page":"9733","DOI":"10.1523\/JNEUROSCI.22-22-09733.2002","volume":"22","author":"T Fath","year":"2002","unstructured":"Fath T, Eidenmuller J, Brandt R (2002) Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer\u2019s disease. J Neurosci 22:9733\u20139741","journal-title":"J Neurosci"},{"key":"1932_CR90","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/21678421.2014.905606","volume":"15","author":"E Feneberg","year":"2014","unstructured":"Feneberg E, Steinacker P, Lehnert S, Schneider A, Walther P, Thal DR et al (2014) Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener 15:351\u2013356. https:\/\/doi.org\/10.3109\/21678421.2014.905606","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1932_CR91","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fnagi.2014.00287","volume":"6","author":"D Ferreira","year":"2014","unstructured":"Ferreira D, Rivero-Santana A, Perestelo-P\u00e9rez L, Westman E, Wahlund LO, Sarr\u00eda A et al (2014) Improving CSF biomarkers\u2019 performance for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease by considering different confounding factors: a meta-analysis. Front Aging Neurosci 6:287. https:\/\/doi.org\/10.3389\/fnagi.2014.00287","journal-title":"Front Aging Neurosci"},{"key":"1932_CR92","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","volume":"14","author":"M Ferretti","year":"2018","unstructured":"Ferretti M, Lulita M, Cavedo E, Chiesa P, Schumacher Dimech A, Chadha Santuccione A et al (2018) Sex-specific phenotypes of Alzheimer\u2019s disease: the gateway to precision neurology. Nat Rev Neurol 14:457\u2013469. https:\/\/doi.org\/10.1038\/s41582-018-0032-9","journal-title":"Nat Rev Neurol"},{"key":"1932_CR93","doi-asserted-by":"publisher","first-page":"348ra396","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"SJ Finnema","year":"2016","unstructured":"Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK et al (2016) Imaging synaptic density in the living human brain. Sci Transl Med 8:348ra396. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6667","journal-title":"Sci Transl Med"},{"key":"1932_CR94","doi-asserted-by":"publisher","first-page":"7856","DOI":"10.1523\/JNEUROSCI.3372-12.2013","volume":"33","author":"D Fleck","year":"2013","unstructured":"Fleck D, van Bebber F, Colombo A, Galante C, Schwenk BM, Rabe L et al (2013) Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. J Neurosci 33:7856\u20137869. https:\/\/doi.org\/10.1523\/JNEUROSCI.3372-12.2013","journal-title":"J Neurosci"},{"key":"1932_CR95","unstructured":"Food and Drug Administration (2011) Guidance for industry\u2014E16 biomarkers related to drug or biotechnology product development: context, structure, and format of qualification submissions. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm267449.pdf"},{"key":"1932_CR96","unstructured":"Food and Drug Administration (2018) Early Alzheimer\u2019s disease: developing drugs for treatment; draft guidance for industry. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM596728.pdf"},{"key":"1932_CR97","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00401-008-0389-8","volume":"116","author":"P Foulds","year":"2008","unstructured":"Foulds P, McAuley E, Gibbons L, Davidson Y, Pickering-Brown SM, Neary D et al (2008) TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Acta Neuropathol 116:141\u2013146. https:\/\/doi.org\/10.1007\/s00401-008-0389-8","journal-title":"Acta Neuropathol"},{"key":"1932_CR98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cca.2015.05.024","volume":"449","author":"A Fourier","year":"2015","unstructured":"Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A (2015) Pre-analytical and analytical factors influencing Alzheimer\u2019s disease cerebrospinal fluid biomarker variability. Clin Chim Acta 449:9\u201315. https:\/\/doi.org\/10.1016\/j.cca.2015.05.024","journal-title":"Clin Chim Acta"},{"key":"1932_CR99","doi-asserted-by":"crossref","unstructured":"Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD et al (2003) Biological markers for therapeutic trials in Alzheimer\u2019s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer\u2019s disease. Neurobiol Aging 24:521\u2013536","DOI":"10.1016\/S0197-4580(03)00002-2"},{"key":"1932_CR100","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K et al (2017) Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol 16:661\u2013676. https:\/\/doi.org\/10.1016\/S1474-4422(17)30159-X","journal-title":"Lancet Neurol"},{"key":"1932_CR101","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archneur.63.4.538","volume":"63","author":"D Galimberti","year":"2006","unstructured":"Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E et al (2006) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 63:538\u2013543. https:\/\/doi.org\/10.1001\/archneur.63.4.538","journal-title":"Arch Neurol"},{"key":"1932_CR102","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1111\/j.1468-1331.2006.01637.x","volume":"14","author":"D Galimberti","year":"2007","unstructured":"Galimberti D, Venturelli E, Fenoglio C, Lovati C, Guidi I, Scalabrini D et al (2007) IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer\u2019s disease. Eur J Neurol 14:e3\u2013e4. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01637.x","journal-title":"Eur J Neurol"},{"key":"1932_CR103","doi-asserted-by":"publisher","unstructured":"Gendron TF, C9ORF72 Neurofilament Study Group, Daughrity LM, Heckman MG, Diehl NN, Wuu J et al (2017) Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol 82:139\u2013146. https:\/\/doi.org\/10.1002\/ana.24980","DOI":"10.1002\/ana.24980"},{"key":"1932_CR104","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/jad-160865","volume":"57","author":"C Gervaise-Henry","year":"2017","unstructured":"Gervaise-Henry C, Watfa G, Albuisson E, Kolodziej A, Dousset B, Olivier JL et al (2017) Cerebrospinal fluid A\u03b2eta42\/A\u03b2eta40 as a means to limiting tube- and storage-dependent pre-analytical variability in clinical setting. J Alzheimers Dis 57:437\u2013445. https:\/\/doi.org\/10.3233\/jad-160865","journal-title":"J Alzheimers Dis"},{"key":"1932_CR105","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.1082324","volume":"300","author":"BI Giasson","year":"2003","unstructured":"Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636\u2013640. https:\/\/doi.org\/10.1126\/science.1082324","journal-title":"Science"},{"key":"1932_CR106","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.dadm.2016.12.002","volume":"6","author":"JD Gispert","year":"2017","unstructured":"Gispert JD, Monte GC, Su\u00e1rez-Calvet M, Falcon C, Tucholka A, Rojas S et al (2017) The APOE \u03b54 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer\u2019s disease but not those of sTREM2. Alzheimers Dement (Amst) 6:50\u201359. https:\/\/doi.org\/10.1016\/j.dadm.2016.12.002","journal-title":"Alzheimers Dement (Amst)"},{"key":"1932_CR107","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jalz.2016.06.005","volume":"12","author":"JD Gispert","year":"2016","unstructured":"Gispert JD, Su\u00e1rez-Calvet M, Mont\u00e9 GC, Tucholka A, Falcon C, Rojas S et al (2016) Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer\u2019s disease. Alzheimers Dement 12:1259\u20131272. https:\/\/doi.org\/10.1016\/j.jalz.2016.06.005","journal-title":"Alzheimers Dement"},{"key":"1932_CR108","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","volume":"122","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alzheimer\u2019s disease and Down\u2019s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:1131\u20131135","journal-title":"Biochem Biophys Res Commun"},{"key":"1932_CR109","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885\u2013890","journal-title":"Biochem Biophys Res Commun"},{"key":"1932_CR110","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1096\/fj.201600816R","volume":"30","author":"EJ Goetzl","year":"2016","unstructured":"Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL et al (2016) Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease. FASEB J 30:4141\u20134148. https:\/\/doi.org\/10.1096\/fj.201600816R","journal-title":"FASEB J"},{"key":"1932_CR111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40478-015-0195-1","volume":"3","author":"J Goossens","year":"2015","unstructured":"Goossens J, Vanmechelen E, Trojanowski JQ, Lee VM, Van Broeckhoven C, van der Zee J et al (2015) TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. Acta Neuropathol Commun 3:15. https:\/\/doi.org\/10.1186\/s40478-015-0195-1","journal-title":"Acta Neuropathol Commun"},{"key":"1932_CR112","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/mp.2017.146","volume":"23","author":"K Goozee","year":"2018","unstructured":"Goozee K, Chatterjee P, James I, Shen K, Sohrabi HR, Asih PR et al (2018) Elevated plasma ferritin in elderly individuals with high neocortical amyloid-beta load. Mol Psychiatry 23:1807\u20131812. https:\/\/doi.org\/10.1038\/mp.2017.146","journal-title":"Mol Psychiatry"},{"key":"1932_CR113","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1074\/jbc.270.13.7013","volume":"270","author":"SA Gravina","year":"1995","unstructured":"Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH et al (1995) Amyloid beta protein (A beta) in Alzheimer\u2019s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270:7013\u20137016","journal-title":"J Biol Chem"},{"key":"1932_CR114","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.biopsych.2009.01.027","volume":"65","author":"T Grimmer","year":"2009","unstructured":"Grimmer T, Riemenschneider M, F\u00f6rstl H, Henriksen G, Klunk WE, Mathis CA et al (2009) Beta amyloid in Alzheimer\u2019s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65:927\u2013934. https:\/\/doi.org\/10.1016\/j.biopsych.2009.01.027","journal-title":"Biol Psychiatry"},{"key":"1932_CR115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/jad-150060","volume":"47","author":"M Groblewska","year":"2015","unstructured":"Groblewska M, Muszynski P, Wojtulewska-Supron A, Kulczynska-Przybik A, Mroczko B (2015) The role of visinin-like protein-1 in the pathophysiology of Alzheimer\u2019s disease. J Alzheimers Dis 47:17\u201332. https:\/\/doi.org\/10.3233\/jad-150060","journal-title":"J Alzheimers Dis"},{"key":"1932_CR116","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al (2013) TREM2 variants in Alzheimer\u2019s disease. N Engl J Med 368:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa1211851","journal-title":"N Engl J Med"},{"key":"1932_CR117","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.biocel.2010.08.015","volume":"42","author":"AP Gunn","year":"2010","unstructured":"Gunn AP, Masters CL, Cherny RA (2010) Pyroglutamate-A\u03b2: role in the natural history of Alzheimer\u2019s disease. Int J Biochem Cell Biol 42:1915\u20131918. https:\/\/doi.org\/10.1016\/j.biocel.2010.08.015","journal-title":"Int J Biochem Cell Biol"},{"key":"1932_CR118","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nm.3457","volume":"20","author":"JL Guo","year":"2014","unstructured":"Guo JL, Lee VM (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20:130\u2013138. https:\/\/doi.org\/10.1038\/nm.3457","journal-title":"Nat Med"},{"key":"1932_CR119","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00406-013-0405-4","volume":"263","author":"LH Guo","year":"2013","unstructured":"Guo LH, Alexopoulos P, Perneczky R (2013) Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci 263:553\u2013560. https:\/\/doi.org\/10.1007\/s00406-013-0405-4","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1932_CR120","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3233\/JAD-170343","volume":"60","author":"R Guo","year":"2017","unstructured":"Guo R, Fan G, Zhang J, Wu C, Du Y, Ye H et al (2017) A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer\u2019s disease. J Alzheimers Dis 60:1365\u20131377. https:\/\/doi.org\/10.3233\/JAD-170343","journal-title":"J Alzheimers Dis"},{"key":"1932_CR121","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton RL (2000) Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378\u2013384","journal-title":"Brain Pathol"},{"key":"1932_CR122","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jalz.2007.08.006","volume":"4","author":"H Hampel","year":"2008","unstructured":"Hampel H, B\u00fcrger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer\u2019s disease. Alzheimers Dement 4:38\u201348. https:\/\/doi.org\/10.1016\/j.jalz.2007.08.006","journal-title":"Alzheimers Dement"},{"key":"1932_CR123","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J et al (2010) Biomarkers for Alzheimer\u2019s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9:560\u2013574. https:\/\/doi.org\/10.1038\/nrd3115","journal-title":"Nat Rev Drug Discov"},{"key":"1932_CR124","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jalz.2012.05.2116","volume":"8","author":"H Hampel","year":"2012","unstructured":"Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all Alzheimer\u2019s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8:312\u2013336. https:\/\/doi.org\/10.1016\/j.jalz.2012.05.2116","journal-title":"Alzheimers Dement"},{"key":"1932_CR125","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.bcp.2013.11.009","volume":"88","author":"H Hampel","year":"2014","unstructured":"Hampel H, Lista S, Teipel SJ, Garaci F, Nistic\u00f3 R, Blennow K et al (2014) Perspective on future role of biological markers in clinical therapy trials of Alzheimer\u2019s disease: a long-range point of view beyond 2020. Biochem Pharmacol 88:426\u2013449. https:\/\/doi.org\/10.1016\/j.bcp.2013.11.009","journal-title":"Biochem Pharmacol"},{"key":"1932_CR126","doi-asserted-by":"publisher","first-page":"243","DOI":"10.14283\/jpad.2016.112","volume":"3","author":"H Hampel","year":"2016","unstructured":"Hampel H, O\u2019Bryant SE, Castrillo JI, Ritchie C, Rojkova K, Broich K et al (2016) PRECISION MEDICINE\u2014the Golden Gate for detection, treatment and prevention of Alzheimer\u2019s disease. J Prev Alzheimers Dis 3:243\u2013259. https:\/\/doi.org\/10.14283\/jpad.2016.112","journal-title":"J Prev Alzheimers Dis"},{"key":"1932_CR127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/13697137.2017.1287866","volume":"20","author":"H Hampel","year":"2017","unstructured":"Hampel H, O\u2019Bryant SE, Durrleman S, Younesi E, Rojkova K, Escott-Price V et al (2017) A precision medicine initiative for Alzheimer\u2019s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric 20:107\u2013118. https:\/\/doi.org\/10.1080\/13697137.2017.1287866","journal-title":"Climacteric"},{"key":"1932_CR128","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, O\u2019Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S et al (2018) Blood-based biomarkers for Alzheimer\u2019s disease: mapping the road to the clinic. Nat Rev Neurol 14:639\u2013652. https:\/\/doi.org\/10.1038\/s41582-018-0079-7","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 1","key":"1932_CR129","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.3233\/JAD-179932","volume":"64","author":"H Hampel","year":"2018","unstructured":"Hampel H, Toschi N, Babiloni C, Baldacci F, Black KL, Bokde ALW et al (2018) Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology. J Alzheimers Dis 64(Suppl 1):S47\u2013S105. https:\/\/doi.org\/10.3233\/JAD-179932","journal-title":"J Alzheimers Dis"},{"key":"1932_CR130","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.phrs.2018.02.014","volume":"130","author":"H Hampel","year":"2018","unstructured":"Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC et al (2018) Precision pharmacology for Alzheimer\u2019s disease. Pharmacol Res 130:331\u2013365. https:\/\/doi.org\/10.1016\/j.phrs.2018.02.014","journal-title":"Pharmacol Res"},{"key":"1932_CR131","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fphys.2017.00005","volume":"8","author":"J Han","year":"2017","unstructured":"Han J, Pluhackova K, B\u00f6ckmann RA (2017) The multifaceted role of SNARE proteins in membrane fusion. Front Physiol 8:5. https:\/\/doi.org\/10.3389\/fphys.2017.00005","journal-title":"Front Physiol"},{"key":"1932_CR132","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/alzrt255","volume":"6","author":"O Hansson","year":"2014","unstructured":"Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L et al (2014) Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson\u2019s disease with dementia and dementia with Lewy bodies compared to Alzheimer\u2019s disease. Alzheimers Res Ther 6:25. https:\/\/doi.org\/10.1186\/alzrt255","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR133","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228\u2013234. https:\/\/doi.org\/10.1016\/S1474-4422(06)70355-6","journal-title":"Lancet Neurol"},{"key":"1932_CR134","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:184\u2013185","journal-title":"Science"},{"key":"1932_CR135","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fnagi.2013.00034","volume":"5","author":"D Hare","year":"2013","unstructured":"Hare D, Ayton S, Bush A, Lei P (2013) A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci 5:34. https:\/\/doi.org\/10.3389\/fnagi.2013.00034","journal-title":"Front Aging Neurosci"},{"key":"1932_CR136","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nm.4443","volume":"24","author":"Z He","year":"2018","unstructured":"He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L et al (2018) Amyloid-\u03b2 plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29\u201338. https:\/\/doi.org\/10.1038\/nm.4443","journal-title":"Nat Med"},{"key":"1932_CR137","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0306-4522(94)00422-2","volume":"64","author":"O Heinonen","year":"1995","unstructured":"Heinonen O, Soininen H, Sorvari H, Kosunen O, Palj\u00e4rvi L, Koivisto E et al (1995) Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer\u2019s disease. Neuroscience 64:375\u2013384","journal-title":"Neuroscience"},{"key":"1932_CR138","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-015-0161-y","volume":"7","author":"K Hellwig","year":"2015","unstructured":"Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P et al (2015) Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer\u2019s disease. Alzheimers Res Ther 7:74. https:\/\/doi.org\/10.1186\/s13195-015-0161-y","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13195-016-0182-1","volume":"8","author":"K Henjum","year":"2016","unstructured":"Henjum K, Almdahl IS, \u00c5rskog V, Minthon L, Hansson O, Fladby T et al (2016) Cerebrospinal fluid soluble TREM2 in aging and Alzheimer\u2019s disease. Alzheimers Res Ther 8:17. https:\/\/doi.org\/10.1186\/s13195-016-0182-1","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR140","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jalz.2013.01.013","volume":"10","author":"K Henriksen","year":"2014","unstructured":"Henriksen K, O\u2019Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A et al (2014) The future of blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement 10:115\u2013131. https:\/\/doi.org\/10.1016\/j.jalz.2013.01.013","journal-title":"Alzheimers Dement"},{"key":"1932_CR141","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P et al (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Mol Neurodegener 11:3. https:\/\/doi.org\/10.1186\/s13024-016-0071-x","journal-title":"Mol Neurodegener"},{"key":"1932_CR142","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12883-016-0707-z","volume":"16","author":"R Hesse","year":"2016","unstructured":"Hesse R, Wahler A, Gummert P, Kirschmer S, Otto M, Tumani H et al (2016) Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1\u03b2. BMC Neurol 16:185. https:\/\/doi.org\/10.1186\/s12883-016-0707-z","journal-title":"BMC Neurol"},{"key":"1932_CR143","doi-asserted-by":"publisher","first-page":"e66381","DOI":"10.1371\/journal.pone.0066381","volume":"8","author":"M H\u00f6ltt\u00e4","year":"2013","unstructured":"H\u00f6ltt\u00e4 M, Hansson O, Andreasson U, Hertze J, Minthon L, N\u00e4gga K et al (2013) Evaluating amyloid-\u03b2 oligomers in cerebrospinal fluid as a biomarker for Alzheimer\u2019s disease. PLoS One 8:e66381. https:\/\/doi.org\/10.1371\/journal.pone.0066381","journal-title":"PLoS One"},{"key":"1932_CR144","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1021\/acschemneuro.5b00324","volume":"7","author":"MH Horrocks","year":"2016","unstructured":"Horrocks MH, Lee SF, Gandhi S, Magdalinou NK, Chen SW, Devine MJ et al (2016) Single-molecule imaging of individual amyloid protein aggregates in human biofluids. ACS Chem Neurosci 7:399\u2013406. https:\/\/doi.org\/10.1021\/acschemneuro.5b00324","journal-title":"ACS Chem Neurosci"},{"key":"1932_CR145","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3233\/jad-130854","volume":"38","author":"N Hu","year":"2014","unstructured":"Hu N, Tan MS, Yu JT, Sun L, Tan L, Wang YL et al (2014) Increased expression of TREM2 in peripheral blood of Alzheimer\u2019s disease patients. J Alzheimers Dis 38:497\u2013501. https:\/\/doi.org\/10.3233\/jad-130854","journal-title":"J Alzheimers Dis"},{"key":"1932_CR146","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","volume":"119","author":"WT Hu","year":"2010","unstructured":"Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM et al (2010) Novel CSF biomarkers for Alzheimer\u2019s disease and mild cognitive impairment. Acta Neuropathol 119:669\u2013678. https:\/\/doi.org\/10.1007\/s00401-010-0667-0","journal-title":"Acta Neuropathol"},{"key":"1932_CR147","doi-asserted-by":"publisher","first-page":"7609","DOI":"10.1021\/bi990438f","volume":"38","author":"X Huang","year":"1999","unstructured":"Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC et al (1999) The A beta peptide of Alzheimer\u2019s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:7609\u20137616. https:\/\/doi.org\/10.1021\/bi990438f","journal-title":"Biochemistry"},{"key":"1932_CR148","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP et al (1999) Improved discrimination of AD patients using \u03b2-amyloid(1-42) and tau levels in CSF. Neurology 52:1555\u20131562","journal-title":"Neurology"},{"key":"1932_CR149","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fneur.2017.00102","volume":"8","author":"RA Huynh","year":"2017","unstructured":"Huynh RA, Mohan C (2017) Alzheimer\u2019s disease: biomarkers in the genome, blood, and cerebrospinal fluid. Front Neurol 8:102. https:\/\/doi.org\/10.3389\/fneur.2017.00102","journal-title":"Front Neurol"},{"key":"1932_CR150","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2174\/1567205012666150710111211","volume":"12","author":"D Inekci","year":"2015","unstructured":"Inekci D, Henriksen K, Linemann T, Karsdal MA, Habib A, Bisgaard C et al (2015) Serum fragments of tau for the differential diagnosis of Alzheimer\u2019s disease. Curr Alzheimer Res 12:829\u2013836","journal-title":"Curr Alzheimer Res"},{"key":"1932_CR151","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fnins.2016.00408","volume":"10","author":"M Ingelsson","year":"2016","unstructured":"Ingelsson M (2016) Alpha-synuclein oligomers-neurotoxic molecules in Parkinson\u2019s disease and other Lewy body disorders. Front Neurosci 10:408. https:\/\/doi.org\/10.3389\/fnins.2016.00408","journal-title":"Front Neurosci"},{"issue":"Suppl 1","key":"1932_CR152","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.parkreldis.2015.09.020","volume":"22","author":"DJ Irwin","year":"2016","unstructured":"Irwin DJ (2016) Tauopathies as clinicopathological entities. Parkinsonism Relat Disord 22(Suppl 1):S29\u2013S33. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.020","journal-title":"Parkinsonism Relat Disord"},{"key":"1932_CR153","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.euroneuro.2011.08.003","volume":"21","author":"M Isaac","year":"2011","unstructured":"Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L (2011) Qualification opinion of novel methodologies in the predementia stage of Alzheimer\u2019s disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden\u2014regulatory considerations by European Medicines Agency focusing in improving benefit\/risk in regulatory trials. Eur Neuropsychopharmacol 21:781\u2013788. https:\/\/doi.org\/10.1016\/j.euroneuro.2011.08.003","journal-title":"Eur Neuropsychopharmacol"},{"key":"1932_CR154","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1038\/ncomms11934","volume":"7","author":"Y Iturria-Medina","year":"2016","unstructured":"Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-P\u00e9rez JM, Evans AC, Alzheimer\u2019s Disease Neuroimaging Initiative (2016) Early role of vascular dysregulation on late-onset Alzheimer\u2019s disease based on multifactorial data-driven analysis. Nat Commun 7:11934. https:\/\/doi.org\/10.1038\/ncomms11934","journal-title":"Nat Commun"},{"key":"1932_CR155","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A\u03b242(43) and A\u03b240 in senile plaques with end-specific A\u03b2 monoclonals: evidence that an initially deposited species is A\u03b242(43). Neuron 13:45\u201353","journal-title":"Neuron"},{"key":"1932_CR156","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207\u2013216. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0","journal-title":"Lancet Neurol"},{"key":"1932_CR157","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.23956","volume":"74","author":"K Jackson","year":"2013","unstructured":"Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F (2013) Amylin deposition in the brain: a second amyloid in Alzheimer disease? Ann Neurol 74:517\u2013526. https:\/\/doi.org\/10.1002\/ana.23956","journal-title":"Ann Neurol"},{"key":"1932_CR158","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","volume":"73","author":"WJ Jagust","year":"2009","unstructured":"Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM et al (2009) Relationships between biomarkers in aging and dementia. Neurology 73:1193\u20131199. https:\/\/doi.org\/10.1212\/WNL.0b013e3181bc010c","journal-title":"Neurology"},{"key":"1932_CR159","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA (2016) TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Brain 139:2983\u20132993. https:\/\/doi.org\/10.1093\/brain\/aww224","journal-title":"Brain"},{"key":"1932_CR160","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A et al (2016) Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep 6:26801. https:\/\/doi.org\/10.1038\/srep26801","journal-title":"Sci Rep"},{"key":"1932_CR161","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O et al (2016) CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3:154\u2013165. https:\/\/doi.org\/10.1002\/acn3.274","journal-title":"Ann Clin Transl Neurol"},{"key":"1932_CR162","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13024-017-0197-5","volume":"12","author":"TR Jay","year":"2017","unstructured":"Jay TR, von Saucken VE, Landreth GE (2017) TREM2 in neurodegenerative diseases. Mol Neurodegener 12:56. https:\/\/doi.org\/10.1186\/s13024-017-0197-5","journal-title":"Mol Neurodegener"},{"key":"1932_CR163","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1212\/01.wnl.0000304041.09418.b1","volume":"70","author":"KA Josephs","year":"2008","unstructured":"Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M et al (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 70:1850\u20131857. https:\/\/doi.org\/10.1212\/01.wnl.0000304041.09418.b1","journal-title":"Neurology"},{"key":"1932_CR164","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nature12481","volume":"501","author":"M Jucker","year":"2013","unstructured":"Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45\u201351. https:\/\/doi.org\/10.1038\/nature12481","journal-title":"Nature"},{"key":"1932_CR165","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000444788","volume":"6","author":"A Junttila","year":"2016","unstructured":"Junttila A, Kuvaja M, Hartikainen P, Siloaho M, Helisalmi S, Moilanen V et al (2016) Cerebrospinal fluid TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis patients with and without the C9ORF72 hexanucleotide expansion. Dement Geriatr Cogn Dis Extra 6:142\u2013149. https:\/\/doi.org\/10.1159\/000444788","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"1932_CR166","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40478-017-0477-x","volume":"5","author":"N Kakuda","year":"2017","unstructured":"Kakuda N, Miyasaka T, Iwasaki N, Nirasawa T, Wada-Kakuda S, Takahashi-Fujigasaki J et al (2017) Distinct deposition of amyloid-beta species in brains with Alzheimer\u2019s disease pathology visualized with MALDI imaging mass spectrometry. Acta Neuropathol Commun 5:73. https:\/\/doi.org\/10.1186\/s40478-017-0477-x","journal-title":"Acta Neuropathol Commun"},{"key":"1932_CR167","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12035-014-9053-6","volume":"53","author":"PK Kamat","year":"2016","unstructured":"Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C et al (2016) Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer\u2019s disease: understanding the therapeutics strategies. Mol Neurobiol 53:648\u2013661. https:\/\/doi.org\/10.1007\/s12035-014-9053-6","journal-title":"Mol Neurobiol"},{"key":"1932_CR168","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jamaneurol.2013.3861","volume":"70","author":"JH Kang","year":"2013","unstructured":"Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS et al (2013) Association of cerebrospinal fluid \u03b2-amyloid 1-42, t-tau, p-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70:1277\u20131287. https:\/\/doi.org\/10.1001\/jamaneurol.2013.3861","journal-title":"JAMA Neurol"},{"key":"1932_CR169","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","volume":"131","author":"JH Kang","year":"2016","unstructured":"Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR et al (2016) CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s Progression Markers Initiative study. Acta Neuropathol 131:935\u2013949. https:\/\/doi.org\/10.1007\/s00401-016-1552-2","journal-title":"Acta Neuropathol"},{"key":"1932_CR170","doi-asserted-by":"publisher","first-page":"e81654","DOI":"10.1371\/journal.pone.0081654","volume":"8","author":"E Kapaki","year":"2013","unstructured":"Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K (2013) The diagnostic value of CSF \u03b1-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer\u2019s disease. PLoS One 8:e81654. https:\/\/doi.org\/10.1371\/journal.pone.0081654","journal-title":"PLoS One"},{"key":"1932_CR171","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00415-014-7334-7","volume":"261","author":"T Kasai","year":"2014","unstructured":"Kasai T, Tokuda T, Ishii R, Ishigami N, Tsuboi Y, Nakagawa M et al (2014) Increased \u03b1-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 261:1203\u20131209. https:\/\/doi.org\/10.1007\/s00415-014-7334-7","journal-title":"J Neurol"},{"key":"1932_CR172","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jnnp.2009.197483","volume":"81","author":"K Kasuga","year":"2010","unstructured":"Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O et al (2010) Differential levels of \u03b1-synuclein, \u03b2-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 81:608\u2013610. https:\/\/doi.org\/10.1136\/jnnp.2009.197483","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1932_CR173","doi-asserted-by":"publisher","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"ME Kennedy","year":"2016","unstructured":"Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF et al (2016) The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer\u2019s disease patients. Sci Transl Med 8:363ra150. https:\/\/doi.org\/10.1126\/scitranslmed.aad9704","journal-title":"Sci Transl Med"},{"key":"1932_CR174","unstructured":"Kerchner G, Ayalon G, Blendstrup M, Brunstein F, Chandra P, Datwani A et al (2017) Targeting tau with RO7105705: Phase I results and design of a Phase II study in prodromal-to-mild AD. Abstract presented at the 10th Clinical Trials on Alzheimer\u2019s Disease (CTAD). Boston (1\u20134 November 2017)"},{"key":"1932_CR175","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P et al (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 72:1275\u20131280. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1867","journal-title":"JAMA Neurol"},{"key":"1932_CR176","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C et al (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimers Res Ther 7:59. https:\/\/doi.org\/10.1186\/s13195-015-0142-1","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR177","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnins.2016.00031","volume":"10","author":"SS Khan","year":"2016","unstructured":"Khan SS, Bloom GS (2016) Tau: the center of a signaling nexus in Alzheimer\u2019s disease. Front Neurosci 10:31. https:\/\/doi.org\/10.3389\/fnins.2016.00031","journal-title":"Front Neurosci"},{"key":"1932_CR178","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3988\/jcn.2016.12.4.381","volume":"12","author":"D Kim","year":"2016","unstructured":"Kim D, Kim YS, Shin DW, Park CS, Kang JH (2016) Harnessing cerebrospinal fluid biomarkers in clinical trials for treating Alzheimer\u2019s and Parkinson\u2019s diseases: potential and challenges. J Clin Neurol 12:381\u2013392. https:\/\/doi.org\/10.3988\/jcn.2016.12.4.381","journal-title":"J Clin Neurol"},{"key":"1932_CR179","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3233\/JAD-143018","volume":"48","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S et al (2015) Elevation of the plasma A\u03b240\/A\u03b242 ratio as a diagnostic marker of sporadic early-onset Alzheimer\u2019s disease. J Alzheimers Dis 48:1043\u20131050. https:\/\/doi.org\/10.3233\/JAD-143018","journal-title":"J Alzheimers Dis"},{"key":"1932_CR180","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1523\/jneurosci.4849-06.2007","volume":"27","author":"J Kim","year":"2007","unstructured":"Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C et al (2007) A\u03b240 inhibits amyloid deposition in vivo. J Neurosci 27:627\u2013633. https:\/\/doi.org\/10.1523\/jneurosci.4849-06.2007","journal-title":"J Neurosci"},{"key":"1932_CR181","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13195-014-0073-2","volume":"6","author":"WS Kim","year":"2014","unstructured":"Kim WS, K\u00e5gedal K, Halliday GM (2014) Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther 6:73. https:\/\/doi.org\/10.1186\/s13195-014-0073-2","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR182","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/acn3.427","volume":"4","author":"M Komori","year":"2017","unstructured":"Komori M, Kosa P, Stein J, Zhao V, Blake A, Cherup J et al (2017) Pharmacodynamic effects of daclizumab in the intrathecal compartment. Ann Clin Transl Neurol 4:478\u2013490. https:\/\/doi.org\/10.1002\/acn3.427","journal-title":"Ann Clin Transl Neurol"},{"key":"1932_CR183","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3233\/jad-130458","volume":"36","author":"A Korff","year":"2013","unstructured":"Korff A, Liu C, Ginghina C, Shi M, Zhang J, Initiative Alzheimer\u2019s Disease Neuroimaging (2013) \u03b1-Synuclein in cerebrospinal fluid of Alzheimer\u2019s disease and mild cognitive impairment. J Alzheimers Dis 36:679\u2013688. https:\/\/doi.org\/10.3233\/jad-130458","journal-title":"J Alzheimers Dis"},{"key":"1932_CR184","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/wnl.0000000000003653","volume":"88","author":"J Kuhle","year":"2017","unstructured":"Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, Yaldizli O et al (2017) Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88:826\u2013831. https:\/\/doi.org\/10.1212\/wnl.0000000000003653","journal-title":"Neurology"},{"key":"1932_CR185","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2016.05.014","volume":"467","author":"J Kuhlmann","year":"2017","unstructured":"Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A et al (2017) CSF Abeta1-42\u2014an excellent but complicated Alzheimer\u2019s biomarker\u2014a route to standardisation. Clin Chim Acta 467:27\u201333. https:\/\/doi.org\/10.1016\/j.cca.2016.05.014","journal-title":"Clin Chim Acta"},{"key":"1932_CR186","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1038\/emboj.2012.173","volume":"31","author":"PH Kuhn","year":"2012","unstructured":"Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M et al (2012) Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J 31:3157\u20133168. https:\/\/doi.org\/10.1038\/emboj.2012.173","journal-title":"EMBO J"},{"key":"1932_CR187","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3233\/jad-160386","volume":"55","author":"HB Kuiperij","year":"2017","unstructured":"Kuiperij HB, Versleijen AA, Beenes M, Verwey NA, Benussi L, Paterlini A et al (2017) Tau rather than TDP-43 proteins are potential cerebrospinal fluid biomarkers for frontotemporal lobar degeneration subtypes: a pilot study. J Alzheimers Dis 55:585\u2013595. https:\/\/doi.org\/10.3233\/jad-160386","journal-title":"J Alzheimers Dis"},{"key":"1932_CR188","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1038\/emboj.2010.211","volume":"29","author":"I Kuperstein","year":"2010","unstructured":"Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M et al (2010) Neurotoxicity of Alzheimer\u2019s disease A\u03b2 peptides is induced by small changes in the A\u03b242 to A\u03b240 ratio. EMBO J 29:3408\u20133420. https:\/\/doi.org\/10.1038\/emboj.2010.211","journal-title":"EMBO J"},{"key":"1932_CR189","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, \u00d6hrfelt A, Andersson K et al (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement 11:1180\u20131190. https:\/\/doi.org\/10.1016\/j.jalz.2014.10.009","journal-title":"Alzheimers Dement"},{"key":"1932_CR190","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N et al (2015) Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther 7:40. https:\/\/doi.org\/10.1186\/s13195-015-0124-3","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR191","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jnnp-2017-316201","volume":"88","author":"KSP Lai","year":"2017","unstructured":"Lai KSP, Liu CS, Rau A, Lanctot KL, Kohler CA, Pakosh M et al (2017) Peripheral inflammatory markers in Alzheimer\u2019s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry 88:876\u2013882. https:\/\/doi.org\/10.1136\/jnnp-2017-316201","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1932_CR192","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1373\/clinchem.2006.070912","volume":"52","author":"OF Laterza","year":"2006","unstructured":"Laterza OF, Modur VR, Crimmins DL, Olander JV, Landt Y, Lee JM et al (2006) Identification of novel brain biomarkers. Clin Chem 52:1713\u20131721. https:\/\/doi.org\/10.1373\/clinchem.2006.070912","journal-title":"Clin Chem"},{"key":"1932_CR193","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fnagi.2017.00210","volume":"9","author":"C Lauridsen","year":"2017","unstructured":"Lauridsen C, Sando SB, Moller I, Berge G, Pomary PK, Grontvedt GR et al (2017) Cerebrospinal fluid Abeta43 Is reduced in early-onset compared to late-onset Alzheimer\u2019s Disease, but has similar diagnostic accuracy to Abeta42. Front Aging Neurosci 9:210. https:\/\/doi.org\/10.3389\/fnagi.2017.00210","journal-title":"Front Aging Neurosci"},{"key":"1932_CR194","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1373\/clinchem.2008.104497","volume":"54","author":"JM Lee","year":"2008","unstructured":"Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J et al (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 54:1617\u20131623. https:\/\/doi.org\/10.1373\/clinchem.2008.104497","journal-title":"Clin Chem"},{"key":"1932_CR195","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","volume":"113","author":"PH Lee","year":"2006","unstructured":"Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K (2006) The plasma alpha-synuclein levels in patients with Parkinson\u2019s disease and multiple system atrophy. J Neural Transm (Vienna) 113:1435\u20131439. https:\/\/doi.org\/10.1007\/s00702-005-0427-9","journal-title":"J Neural Transm (Vienna)"},{"key":"1932_CR196","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1126\/science.1899488","volume":"251","author":"VM Lee","year":"1991","unstructured":"Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 251:675\u2013678","journal-title":"Science"},{"key":"1932_CR197","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1212\/WNL.56.suppl_4.S26","volume":"56","author":"VM Lee","year":"2001","unstructured":"Lee VM, Trojanowski JQ (2001) Transgenic mouse models of tauopathies: prospects for animal models of Pick\u2019s disease. Neurology 56:S26\u2013S30","journal-title":"Neurology"},{"key":"1932_CR198","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fneur.2015.00153","volume":"6","author":"MJ Leit\u00e3o","year":"2015","unstructured":"Leit\u00e3o MJ, Baldeiras I, Herukka SK, Pikkarainen M, Leinonen V, Simonsen AH et al (2015) Chasing the effects of pre-analytical confounders\u2014a multicenter study on CSF-AD biomarkers. Front Neurol 6:153. https:\/\/doi.org\/10.3389\/fneur.2015.00153","journal-title":"Front Neurol"},{"key":"1932_CR199","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","volume":"88","author":"AW Lemstra","year":"2017","unstructured":"Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM et al (2017) Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 88:113\u2013118. https:\/\/doi.org\/10.1136\/jnnp-2016-313775","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1932_CR200","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/j.1471-4159.2006.04435.x","volume":"101","author":"J Leschik","year":"2007","unstructured":"Leschik J, Welzel A, Weissmann C, Eckert A, Brandt R (2007) Inverse and distinct modulation of tau-dependent neurodegeneration by presenilin 1 and amyloid-\u03b2 in cultured cortical neurons: evidence that tau phosphorylation is the limiting factor in amyloid-\u03b2-induced cell death. J Neurochem 101:1303\u20131315. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04435.x","journal-title":"J Neurochem"},{"key":"1932_CR201","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.dadm.2015.06.008","volume":"1","author":"YY Leung","year":"2015","unstructured":"Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX et al (2015) Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer\u2019s disease in a multicohort study. Alzheimers Dement (Amst) 1:339\u2013348. https:\/\/doi.org\/10.1016\/j.dadm.2015.06.008","journal-title":"Alzheimers Dement (Amst)"},{"key":"1932_CR202","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/brain\/aww160","volume":"139","author":"A Leuzy","year":"2016","unstructured":"Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendon\u00e7a A, Otto M et al (2016) Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study. Brain 139:2540\u20132553. https:\/\/doi.org\/10.1093\/brain\/aww160","journal-title":"Brain"},{"key":"1932_CR203","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archneur.63.3.370","volume":"63","author":"JB Leverenz","year":"2006","unstructured":"Leverenz JB, Fishel MA, Peskind ER, Montine TJ, Nochlin D, Steinbart E et al (2006) Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol 63:370\u2013376. https:\/\/doi.org\/10.1001\/archneur.63.3.370","journal-title":"Arch Neurol"},{"key":"1932_CR204","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/JAD-160448","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Lelental N, Lachmann I, Holzer M, Flach K, Brandner S et al (2017) Non-phosphorylated tau as a potential biomarker of Alzheimer\u2019s disease: analytical and diagnostic characterization. J Alzheimers Dis 55:159\u2013170. https:\/\/doi.org\/10.3233\/JAD-160448","journal-title":"J Alzheimers Dis"},{"key":"1932_CR205","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/jad-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P et al (2017) Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis 55:813\u2013822. https:\/\/doi.org\/10.3233\/jad-160722","journal-title":"J Alzheimers Dis"},{"key":"1932_CR206","doi-asserted-by":"publisher","unstructured":"Lewczuk P, Riederer P, O\u2019Bryant SE, Verbeek MM, Dubois B, Visser PJ et al (2017) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. https:\/\/doi.org\/10.1080\/15622975.2017.1375556","DOI":"10.1080\/15622975.2017.1375556"},{"key":"1932_CR207","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.2353\/ajpath.2010.100552","volume":"177","author":"KA Lewis","year":"2010","unstructured":"Lewis KA, Su Y, Jou O, Ritchie C, Foong C, Hynan LS et al (2010) Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer\u2019s disease without conventional Lewy body pathology. Am J Pathol 177:3037\u20133050. https:\/\/doi.org\/10.2353\/ajpath.2010.100552","journal-title":"Am J Pathol"},{"key":"1932_CR208","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/alzrt249","volume":"6","author":"T Leyhe","year":"2014","unstructured":"Leyhe T, Andreasen N, Simeoni M, Reich A, von Arnim CA, Tong X et al (2014) Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer\u2019s disease: a phase I study. Alzheimers Res Ther 6:19. https:\/\/doi.org\/10.1186\/alzrt249","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR209","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/01.wnl.0000267428.62582.aa","volume":"69","author":"G Li","year":"2007","unstructured":"Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD et al (2007) CSF tau\/A\u03b242 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69:631\u2013639. https:\/\/doi.org\/10.1212\/01.wnl.0000267428.62582.aa","journal-title":"Neurology"},{"key":"1932_CR210","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s13311-015-0378-2","volume":"12","author":"X Li","year":"2015","unstructured":"Li X, Lei P, Tuo Q, Ayton S, Li QX, Moon S et al (2015) Enduring elevations of hippocampal amyloid precursor protein and iron are features of \u03b2-amyloid toxicity and are mediated by tau. Neurotherapeutics 12:862\u2013873. https:\/\/doi.org\/10.1007\/s13311-015-0378-2","journal-title":"Neurotherapeutics"},{"key":"1932_CR211","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1189\/jlb.3VMR0415-142R","volume":"98","author":"S Libreros","year":"2015","unstructured":"Libreros S, Iragavarapu-Charyulu V (2015) YKL-40\/CHI3L1 drives inflammation on the road of tumor progression. J Leukoc Biol 98:931\u2013936. https:\/\/doi.org\/10.1189\/jlb.3VMR0415-142R","journal-title":"J Leukoc Biol"},{"key":"1932_CR212","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","volume":"88","author":"CH Lin","year":"2017","unstructured":"Lin CH, Yang SY, Horng HE, Yang CC, Chieh JJ, Chen HH et al (2017) Plasma \u03b1-synuclein predicts cognitive decline in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 88:818\u2013824. https:\/\/doi.org\/10.1136\/jnnp-2016-314857","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1932_CR213","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4","volume":"45","author":"CF Lippa","year":"1999","unstructured":"Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down\u2019s syndrome brains with Alzheimer\u2019s disease. Ann Neurol 45:353\u2013357","journal-title":"Ann Neurol"},{"key":"1932_CR214","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2217\/bmm.11.50","volume":"5","author":"S Lista","year":"2011","unstructured":"Lista S, Emanuele E (2011) Role of amyloid beta1-42 and neuroimaging biomarkers in Alzheimer\u2019s disease. Biomark Med 5:411\u2013413. https:\/\/doi.org\/10.2217\/bmm.11.50","journal-title":"Biomark Med"},{"key":"1932_CR215","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pneurobio.2012.06.006","volume":"101\u2013102","author":"S Lista","year":"2013","unstructured":"Lista S, Faltraco F, Hampel H (2013) Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol 101\u2013102:18\u201334. https:\/\/doi.org\/10.1016\/j.pneurobio.2012.06.006","journal-title":"Prog Neurobiol"},{"key":"1932_CR216","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.06.007","volume":"101\u2013102","author":"S Lista","year":"2013","unstructured":"Lista S, Faltraco F, Prvulovic D, Hampel H (2013) Blood and plasma-based proteomic biomarker research in Alzheimer\u2019s disease. Prog Neurobiol 101\u2013102:1\u201317. https:\/\/doi.org\/10.1016\/j.pneurobio.2012.06.007","journal-title":"Prog Neurobiol"},{"key":"1932_CR217","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jalz.2013.04.506","volume":"10","author":"S Lista","year":"2014","unstructured":"Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K et al (2014) CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer\u2019s disease. Alzheimers Dement 10:381\u2013392. https:\/\/doi.org\/10.1016\/j.jalz.2013.04.506","journal-title":"Alzheimers Dement"},{"key":"1932_CR218","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14737175.2016.1204234","volume":"17","author":"S Lista","year":"2017","unstructured":"Lista S, Hampel H (2017) Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer\u2019s disease. Expert Rev Neurother 17:47\u201357. https:\/\/doi.org\/10.1080\/14737175.2016.1204234","journal-title":"Expert Rev Neurother"},{"key":"1932_CR219","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-1-4939-2627-5_2","volume":"1303","author":"S Lista","year":"2016","unstructured":"Lista S, Khachaturian ZS, Rujescu D, Garaci F, Dubois B, Hampel H (2016) Application of systems theory in longitudinal studies on the origin and progression of Alzheimer\u2019s disease. Methods Mol Biol 1303:49\u201367. https:\/\/doi.org\/10.1007\/978-1-4939-2627-5_2","journal-title":"Methods Mol Biol"},{"key":"1932_CR220","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neuint.2017.05.010","volume":"108","author":"S Lista","year":"2017","unstructured":"Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I et al (2017) Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer\u2019s disease. Neurochem Int 108:355\u2013360. https:\/\/doi.org\/10.1016\/j.neuint.2017.05.010","journal-title":"Neurochem Int"},{"key":"1932_CR221","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3233\/jad-170368","volume":"59","author":"S Lista","year":"2017","unstructured":"Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I et al (2017) Cerebrospinal fluid neurogranin as a biomarker of neurodegenerative diseases: a cross-sectional study. J Alzheimers Dis 59:1327\u20131334. https:\/\/doi.org\/10.3233\/jad-170368","journal-title":"J Alzheimers Dis"},{"key":"1932_CR222","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-4939-6952-4_5","volume":"1598","author":"S Lista","year":"2017","unstructured":"Lista S, Zetterberg H, O\u2019Bryant SE, Blennow K, Hampel H (2017) Evolving relevance of neuroproteomics in Alzheimer\u2019s disease. Methods Mol Biol 1598:101\u2013115. https:\/\/doi.org\/10.1007\/978-1-4939-6952-4_5","journal-title":"Methods Mol Biol"},{"key":"1932_CR223","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cytogfr.2011.06.001","volume":"22","author":"M Liu","year":"2011","unstructured":"Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO et al (2011) CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22:121\u2013130. https:\/\/doi.org\/10.1016\/j.cytogfr.2011.06.001","journal-title":"Cytokine Growth Factor Rev"},{"key":"1932_CR224","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1089\/neu.2016.4496","volume":"34","author":"J Ljungqvist","year":"2017","unstructured":"Ljungqvist J, Zetterberg H, Mitsis M, Blennow K, Skoglund T (2017) Serum neurofilament light protein as a marker for diffuse axonal injury: results from a case series study. J Neurotrauma 34:1124\u20131127. https:\/\/doi.org\/10.1089\/neu.2016.4496","journal-title":"J Neurotrauma"},{"key":"1932_CR225","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s12035-017-0479-5","volume":"55","author":"F Llorens","year":"2017","unstructured":"Llorens F, Kruse N, Karch A, Schmitz M, Zafar S, Gotzmann N et al (2017) Validation of \u03b1-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease. Mol Neurobiol 55:2249\u20132257. https:\/\/doi.org\/10.1007\/s12035-017-0479-5","journal-title":"Mol Neurobiol"},{"key":"1932_CR226","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1046\/j.1471-4159.1995.65020710.x","volume":"65","author":"DA Loeffler","year":"1995","unstructured":"Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ et al (1995) Transferrin and iron in normal, Alzheimer\u2019s disease, and Parkinson\u2019s disease brain regions. J Neurochem 65:710\u2013724","journal-title":"J Neurochem"},{"key":"1932_CR227","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jalz.2016.12.004","volume":"13","author":"H L\u00f6vheim","year":"2017","unstructured":"L\u00f6vheim H, Elgh F, Johansson A, Zetterberg H, Blennow K, Hallmans G et al (2017) Plasma concentrations of free amyloid \u03b2 cannot predict the development of Alzheimer\u2019s disease. Alzheimers Dement 13:778\u2013782. https:\/\/doi.org\/10.1016\/j.jalz.2016.12.004","journal-title":"Alzheimers Dement"},{"key":"1932_CR228","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"CH Lu","year":"2015","unstructured":"Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N et al (2015) Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84:2247\u20132257. https:\/\/doi.org\/10.1212\/WNL.0000000000001642","journal-title":"Neurology"},{"key":"1932_CR229","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ et al (2012) Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949\u2013953. https:\/\/doi.org\/10.1126\/science.1227157","journal-title":"Science"},{"key":"1932_CR230","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/jnc.12331","volume":"127","author":"X Luo","year":"2013","unstructured":"Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D et al (2013) CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer\u2019s disease and dementia with Lewy bodies. J Neurochem 127:681\u2013690. https:\/\/doi.org\/10.1111\/jnc.12331","journal-title":"J Neurochem"},{"key":"1932_CR231","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/jnnp.64.3.402","volume":"64","author":"JN Lycke","year":"1998","unstructured":"Lycke JN, Karlsson JE, Andersen O, Rosengren LE (1998) Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64:402\u2013404","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1932_CR232","doi-asserted-by":"publisher","first-page":"40263","DOI":"10.1038\/srep40263","volume":"7","author":"NK Majbour","year":"2017","unstructured":"Majbour NK, Chiasserini D, Vaikath NN, Eusebi P, Tokuda T, van de Berg W et al (2017) Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer\u2019s disease. Sci Rep 7:40263. https:\/\/doi.org\/10.1038\/srep40263","journal-title":"Sci Rep"},{"key":"1932_CR233","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB et al (2016) Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease. Mol Neurodegener 11:7. https:\/\/doi.org\/10.1186\/s13024-016-0072-9","journal-title":"Mol Neurodegener"},{"key":"1932_CR234","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/alzrt109","volume":"4","author":"SE Marsh","year":"2012","unstructured":"Marsh SE, Blurton-Jones M (2012) Examining the mechanisms that link \u03b2-amyloid and \u03b1-synuclein pathologies. Alzheimers Res Ther 4:11. https:\/\/doi.org\/10.1186\/alzrt109","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR235","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/BF00293464","volume":"81","author":"E Masliah","year":"1991","unstructured":"Masliah E, Hansen L, Albright T, Mallory M, Terry RD (1991) Immunoelectron microscopic study of synaptic pathology in Alzheimer\u2019s disease. Acta Neuropathol 81:428\u2013433","journal-title":"Acta Neuropathol"},{"key":"1932_CR236","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr et al (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease. Neurology 56:127\u2013129","journal-title":"Neurology"},{"key":"1932_CR237","first-page":"235","volume":"138","author":"E Masliah","year":"1991","unstructured":"Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA (1991) Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer\u2019s disease. Am J Pathol 138:235\u2013246","journal-title":"Am J Pathol"},{"key":"1932_CR238","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer\u2019s disease. Nat Rev Dis Primers 1:15056. https:\/\/doi.org\/10.1038\/nrdp.2015.56","journal-title":"Nat Rev Dis Primers"},{"key":"1932_CR239","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245\u20134249","journal-title":"Proc Natl Acad Sci USA"},{"key":"1932_CR240","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging Initiative (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 74:557\u2013566. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117","journal-title":"JAMA Neurol"},{"key":"1932_CR241","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.dadm.2015.09.001","volume":"1","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Carrillo MC, Dean RA, Devous MD Sr, Nikolcheva T, Pesini P et al (2015) Revolutionizing Alzheimer\u2019s disease and clinical trials through biomarkers. Alzheimers Dement (Amst) 1:412\u2013419. https:\/\/doi.org\/10.1016\/j.dadm.2015.09.001","journal-title":"Alzheimers Dement (Amst)"},{"key":"1932_CR242","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M et al (2016) Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol Med 8:1184\u20131196. https:\/\/doi.org\/10.15252\/emmm.201606540","journal-title":"EMBO Mol Med"},{"key":"1932_CR243","doi-asserted-by":"publisher","first-page":"10918","DOI":"10.1038\/ncomms10918","volume":"7","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Stomrud E, van Westen D, Minthon L et al (2016) Increased amyloidogenic APP processing in APOE \u025b4-negative individuals with cerebral \u03b2-amyloidosis. Nat Commun 7:10918. https:\/\/doi.org\/10.1038\/ncomms10918","journal-title":"Nat Commun"},{"key":"1932_CR244","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","volume":"13","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, M\u00e5nsson JE et al (2011) Cerebrospinal fluid microglial markers in Alzheimer\u2019s disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromol Med 13:151\u2013159. https:\/\/doi.org\/10.1007\/s12017-011-8147-9","journal-title":"Neuromol Med"},{"key":"1932_CR245","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E et al (2016) Plasma tau in Alzheimer disease. Neurology 87:1827\u20131835. https:\/\/doi.org\/10.1212\/WNL.0000000000003246","journal-title":"Neurology"},{"key":"1932_CR246","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuron.2005.06.030","volume":"47","author":"E McGowan","year":"2005","unstructured":"McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C et al (2005) A\u03b242 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191\u2013199. https:\/\/doi.org\/10.1016\/j.neuron.2005.06.030","journal-title":"Neuron"},{"key":"1932_CR247","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"key":"1932_CR248","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57:100\u2013105","journal-title":"Arch Neurol"},{"key":"1932_CR249","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/ene.13162","volume":"24","author":"J Mellerg\u00e5rd","year":"2017","unstructured":"Mellerg\u00e5rd J, Tisell A, Blystad I, Gr\u00f6nqvist A, Blennow K, Olsson B et al (2017) Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol 24:112\u2013121. https:\/\/doi.org\/10.1111\/ene.13162","journal-title":"Eur J Neurol"},{"key":"1932_CR250","doi-asserted-by":"publisher","first-page":"e76523","DOI":"10.1371\/journal.pone.0076523","volume":"8","author":"JE Meredith Jr","year":"2013","unstructured":"Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ et al (2013) Characterization of novel CSF tau and ptau biomarkers for Alzheimer\u2019s disease. PLoS One 8:e76523. https:\/\/doi.org\/10.1371\/journal.pone.0076523","journal-title":"PLoS One"},{"key":"1932_CR251","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","volume":"74","author":"MM Mielke","year":"2017","unstructured":"Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, Knopman DS et al (2017) Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging. JAMA Neurol 74:1073\u20131080. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1359","journal-title":"JAMA Neurol"},{"key":"1932_CR252","first-page":"II-35-41","volume":"77","author":"N Mohorko","year":"2008","unstructured":"Mohorko N, Bresjanac M (2008) Tau protein and human tauopathies: an overview. Zdrav Vestn 77:II-35-41","journal-title":"Zdrav Vestn"},{"key":"1932_CR253","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","volume":"213","author":"B Mollenhauer","year":"2008","unstructured":"Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I et al (2008) Direct quantification of CSF \u03b1-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213:315\u2013325. https:\/\/doi.org\/10.1016\/j.expneurol.2008.06.004","journal-title":"Exp Neurol"},{"key":"1932_CR254","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000105157","volume":"4","author":"B Mollenhauer","year":"2007","unstructured":"Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG et al (2007) Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis 4:366\u2013375. https:\/\/doi.org\/10.1159\/000105157","journal-title":"Neurodegener Dis"},{"key":"1932_CR255","doi-asserted-by":"publisher","first-page":"e0136835","DOI":"10.1371\/journal.pone.0136835","volume":"10","author":"Y Mori","year":"2015","unstructured":"Mori Y, Yoshino Y, Ochi S, Yamazaki K, Kawabe K, Abe M et al (2015) TREM2 mRNA expression in leukocytes is increased in Alzheimer\u2019s disease and schizophrenia. PLoS One 10:e0136835. https:\/\/doi.org\/10.1371\/journal.pone.0136835","journal-title":"PLoS One"},{"key":"1932_CR256","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D et al (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. Ann Neurol 38:643\u2013648. https:\/\/doi.org\/10.1002\/ana.410380413","journal-title":"Ann Neurol"},{"key":"1932_CR257","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3233\/jad-141050","volume":"43","author":"B Mroczko","year":"2015","unstructured":"Mroczko B, Groblewska M, Zboch M, Muszynski P, Zajkowska A, Borawska R et al (2015) Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer\u2019s disease. J Alzheimers Dis 43:1031\u20131037. https:\/\/doi.org\/10.3233\/jad-141050","journal-title":"J Alzheimers Dis"},{"key":"1932_CR258","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/jad-2010-1367","volume":"20","author":"SD Mulder","year":"2010","unstructured":"Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA et al (2010) BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis 20:253\u2013260. https:\/\/doi.org\/10.3233\/jad-2010-1367","journal-title":"J Alzheimers Dis"},{"key":"1932_CR259","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/jnnp.2009.199398","volume":"82","author":"E Mulugeta","year":"2011","unstructured":"Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K et al (2011) CSF amyloid \u03b238 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 82:160\u2013164. https:\/\/doi.org\/10.1136\/jnnp.2009.199398","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1932_CR260","doi-asserted-by":"publisher","unstructured":"Naj AC, Schellenberg GD, Alzheimer\u2019s Disease Genetics Consortium (2017) Genomic variants, genes, and pathways of Alzheimer\u2019s disease: an overview. Am J Med Genet B Neuropsychiatr Genet 174:5\u201326. https:\/\/doi.org\/10.1002\/ajmg.b.32499","DOI":"10.1002\/ajmg.b.32499"},{"key":"1932_CR261","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V et al (2018) High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554:249\u2013254. https:\/\/doi.org\/10.1038\/nature25456","journal-title":"Nature"},{"key":"1932_CR262","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(17)32451-0","volume":"391","author":"S Nath","year":"2017","unstructured":"Nath S, Koziarz A, Badhiwala JH, Alhazzani W, Jaeschke R, Sharma S et al (2017) Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet 391:1197\u20131204. https:\/\/doi.org\/10.1016\/S0140-6736(17)32451-0","journal-title":"Lancet"},{"key":"1932_CR263","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362\u2013381. https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7","journal-title":"J Neuropathol Exp Neurol"},{"key":"1932_CR264","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/JAD-2011-101641","volume":"25","author":"K Neumann","year":"2011","unstructured":"Neumann K, Far\u00edas G, Slachevsky A, Perez P, Maccioni RB (2011) Human platelets tau: a potential peripheral marker for Alzheimer\u2019s disease. J Alzheimers Dis 25:103\u2013109. https:\/\/doi.org\/10.3233\/JAD-2011-101641","journal-title":"J Alzheimers Dis"},{"key":"1932_CR265","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130\u2013133. https:\/\/doi.org\/10.1126\/science.1134108","journal-title":"Science"},{"key":"1932_CR266","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jnc.13881","volume":"141","author":"L Novakova","year":"2017","unstructured":"Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmestr\u00f6m C et al (2017) Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem 141:296\u2013304. https:\/\/doi.org\/10.1111\/jnc.13881","journal-title":"J Neurochem"},{"key":"1932_CR267","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/1352458516639384","volume":"23","author":"L Novakova","year":"2017","unstructured":"Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmestr\u00f6m C et al (2017) Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler 23:62\u201371. https:\/\/doi.org\/10.1177\/1352458516639384","journal-title":"Mult Scler"},{"key":"1932_CR268","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jalz.2014.08.099","volume":"11","author":"SE O\u2019Bryant","year":"2015","unstructured":"O\u2019Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S et al (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer\u2019s disease research. Alzheimers Dement 11:549\u2013560. https:\/\/doi.org\/10.1016\/j.jalz.2014.08.099","journal-title":"Alzheimers Dement"},{"key":"1932_CR269","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","volume":"13","author":"SE O\u2019Bryant","year":"2017","unstructured":"O\u2019Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H et al (2017) Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement 13:45\u201358. https:\/\/doi.org\/10.1016\/j.jalz.2016.09.014","journal-title":"Alzheimers Dement"},{"key":"1932_CR270","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","volume":"8","author":"A \u00d6hrfelt","year":"2016","unstructured":"\u00d6hrfelt A, Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H et al (2016) The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther 8:41. https:\/\/doi.org\/10.1186\/s13195-016-0208-8","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR271","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15:673\u2013684. https:\/\/doi.org\/10.1016\/s1474-4422(16)00070-3","journal-title":"Lancet Neurol"},{"key":"1932_CR272","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1074\/jbc.M113.498246","volume":"289","author":"F Olsson","year":"2014","unstructured":"Olsson F, Schmidt S, Althoff V, Munter LM, Jin S, Rosqvist S et al (2014) Characterization of intermediate steps in amyloid beta (A\u03b2) production under near-native conditions. J Biol Chem 289:1540\u20131550. https:\/\/doi.org\/10.1074\/jbc.M113.498246","journal-title":"J Biol Chem"},{"key":"1932_CR273","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T et al (2017) Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13:841\u2013849. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2266","journal-title":"Alzheimers Dement"},{"key":"1932_CR274","unstructured":"Palmqvist S, Janelidze S, Stromrud E, Zetterberg H, Karl J, Mattsson N et al (2018) Detecting brain amyloid status using fully automated plasma A\u03b2 biomarker assays. Abstract presented at the Alzheimer\u2019s Association International Conference (AAIC) 2018. Chicago (22\u201326 July 2018)"},{"key":"1932_CR275","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Alzheimer\u2019s Disease Neuroimaging Initiative, Minthon L et al (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85:1240\u20131249. https:\/\/doi.org\/10.1212\/wnl.0000000000001991","DOI":"10.1212\/wnl.0000000000001991"},{"key":"1932_CR276","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H et al (2016) Reference measurement procedure for CSF amyloid beta (A\u03b2)1-42 and the CSF A\u03b21-42\/A\u03b21-40 ratio\u2014a cross-validation study against amyloid PET. J Neurochem 139:651\u2013658. https:\/\/doi.org\/10.1111\/jnc.13838","journal-title":"J Neurochem"},{"key":"1932_CR277","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neulet.2014.04.041","volume":"573","author":"J Pannee","year":"2014","unstructured":"Pannee J, T\u00f6rnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G et al (2014) The amyloid-\u03b2 degradation pattern in plasma\u2014a possible tool for clinical trials in Alzheimer\u2019s disease. Neurosci Lett 573:7\u201312. https:\/\/doi.org\/10.1016\/j.neulet.2014.04.041","journal-title":"Neurosci Lett"},{"key":"1932_CR278","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-017-0248-8","volume":"9","author":"JC Park","year":"2017","unstructured":"Park JC, Han SH, Cho HJ, Byun MS, Yi D, Choe YM et al (2017) Chemically treated plasma A\u03b2 is a potential blood-based biomarker for screening cerebral amyloid deposition. Alzheimers Res Ther 9:20. https:\/\/doi.org\/10.1186\/s13195-017-0248-8","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR279","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000445452","volume":"39","author":"L Parnetti","year":"2016","unstructured":"Parnetti L, Eusebi P, Lle\u00f3 A (2016) Cerebrospinal fluid biomarkers for target engagement and efficacy in clinical trials for Alzheimer\u2019s and Parkinson\u2019s diseases. Front Neurol Neurosci 39:117\u2013123. https:\/\/doi.org\/10.1159\/000445452","journal-title":"Front Neurol Neurosci"},{"key":"1932_CR280","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2016.11.005","volume":"13","author":"TA Pascoal","year":"2017","unstructured":"Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S et al (2017) Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement 13:644\u2013653. https:\/\/doi.org\/10.1016\/j.jalz.2016.11.005","journal-title":"Alzheimers Dement"},{"key":"1932_CR281","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/cercor\/bhx294","volume":"28","author":"JB Pereira","year":"2018","unstructured":"Pereira JB, Strandberg TO, Palmqvist S, Volpe G, van Westen D, Westman E et al (2018) Amyloid network topology characterizes the progression of Alzheimer\u2019s disease during the predementia stages. Cereb Cortex 28:340\u2013349. https:\/\/doi.org\/10.1093\/cercor\/bhx294","journal-title":"Cereb Cortex"},{"key":"1932_CR282","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurobiolaging.2017.06.002","volume":"58","author":"JB Pereira","year":"2017","unstructured":"Pereira JB, Westman E, Hansson O, Alzheimer\u2019s Disease Neuroimaging Initiative (2017) Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer\u2019s disease. Neurobiol Aging 58:14\u201329. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.06.002","journal-title":"Neurobiol Aging"},{"key":"1932_CR283","doi-asserted-by":"publisher","unstructured":"Perneczky R, Alexopoulos P, Alzheimer\u2019s Disease Neuroimaging Initiative (2014) Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer\u2019s disease. Alzheimers Dement 10:S425\u2013S429 e421. https:\/\/doi.org\/10.1016\/j.jalz.2013.09.006","DOI":"10.1016\/j.jalz.2013.09.006"},{"key":"1932_CR284","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-2012-120361","volume":"31","author":"A Perret-Liaudet","year":"2012","unstructured":"Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W et al (2012) Risk of Alzheimer\u2019s disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 31:13\u201320. https:\/\/doi.org\/10.3233\/JAD-2012-120361","journal-title":"J Alzheimers Dis"},{"key":"1932_CR285","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ana.23931","volume":"74","author":"RC Petersen","year":"2013","unstructured":"Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS et al (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74:199\u2013208. https:\/\/doi.org\/10.1002\/ana.23931","journal-title":"Ann Neurol"},{"key":"1932_CR286","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000101843","volume":"4","author":"A Petzold","year":"2007","unstructured":"Petzold A, Keir G, Warren J, Fox N, Rossor MN (2007) A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 4:185\u2013194. https:\/\/doi.org\/10.1159\/000101843","journal-title":"Neurodegener Dis"},{"key":"1932_CR287","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-\u00c1guila JL, Ghezzi L, Holtzman DM, Fagan AM et al (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131:925\u2013933. https:\/\/doi.org\/10.1007\/s00401-016-1533-5","journal-title":"Acta Neuropathol"},{"key":"1932_CR288","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000099473","volume":"23","author":"YA Pijnenburg","year":"2007","unstructured":"Pijnenburg YA, Janssen JC, Schoonenboom NS, Petzold A, Mulder C, Stigbrand T et al (2007) CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer\u2019s disease and controls. Dement Geriatr Cogn Disord 23:225\u2013230. https:\/\/doi.org\/10.1159\/000099473","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1932_CR289","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.neurobiolaging.2009.06.002","volume":"32","author":"E Portelius","year":"2011","unstructured":"Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R et al (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32:1090\u20131098. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.06.002","journal-title":"Neurobiol Aging"},{"key":"1932_CR290","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1021\/pr050475v","volume":"5","author":"E Portelius","year":"2006","unstructured":"Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K (2006) Determination of \u03b2-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 5:1010\u20131016. https:\/\/doi.org\/10.1021\/pr050475v","journal-title":"J Proteome Res"},{"key":"1932_CR291","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillback T, Tornqvist U, Andreasson U, Trojanowski JQ et al (2015) Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain 138:3373\u20133385. https:\/\/doi.org\/10.1093\/brain\/awv267","journal-title":"Brain"},{"key":"1932_CR292","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1021\/acs.jproteome.6b00829","volume":"16","author":"G Pottiez","year":"2017","unstructured":"Pottiez G, Yang L, Stewart T, Song N, Aro P, Galasko DR et al (2017) Mass-spectrometry-based method to quantify in parallel tau and amyloid beta 1-42 in CSF for the diagnosis of Alzheimer\u2019s disease. J Proteome Res 16:1228\u20131238. https:\/\/doi.org\/10.1021\/acs.jproteome.6b00829","journal-title":"J Proteome Res"},{"key":"1932_CR293","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12974-017-0893-7","volume":"14","author":"M Querol-Vilaseca","year":"2017","unstructured":"Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Mart\u00edn-Paniello C, Clarimon J, Belbin O et al (2017) YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer\u2019s disease and other tauopathies. J Neuroinflammation 14:118. https:\/\/doi.org\/10.1186\/s12974-017-0893-7","journal-title":"J Neuroinflammation"},{"key":"1932_CR294","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.dadm.2015.11.006","volume":"2","author":"AM Racine","year":"2016","unstructured":"Racine AM, Koscik RL, Nicholas CR, Clark LR, Okonkwo OC, Oh JM et al (2016) Cerebrospinal fluid ratios with A\u03b242 predict preclinical brain \u03b2-amyloid accumulation. Alzheimers Dement (Amst) 2:27\u201338. https:\/\/doi.org\/10.1016\/j.dadm.2015.11.006","journal-title":"Alzheimers Dement (Amst)"},{"key":"1932_CR295","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrneurol.2017.1","volume":"13","author":"EM Reiman","year":"2017","unstructured":"Reiman EM (2017) Alzheimer disease in 2016: putting AD treatments and biomarkers to the test. Nat Rev Neurol 13:74\u201376. https:\/\/doi.org\/10.1038\/nrneurol.2017.1","journal-title":"Nat Rev Neurol"},{"key":"1932_CR296","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/sj\/mn\/7800086","volume":"8","author":"JA Rhodin","year":"2001","unstructured":"Rhodin JA, Thomas T (2001) A vascular connection to Alzheimer\u2019s disease. Microcirculation 8:207\u2013220. https:\/\/doi.org\/10.1038\/sj\/mn\/7800086","journal-title":"Microcirculation"},{"key":"1932_CR297","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/sj.mp.4001220","volume":"8","author":"M Riemenschneider","year":"2003","unstructured":"Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H et al (2003) Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 8:343\u2013347. https:\/\/doi.org\/10.1038\/sj.mp.4001220","journal-title":"Mol Psychiatry"},{"key":"1932_CR298","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fneur.2015.00186","volume":"6","author":"A Ritter","year":"2015","unstructured":"Ritter A, Cummings J (2015) Fluid biomarkers in clinical trials of Alzheimer\u2019s disease therapeutics. Front Neurol 6:186. https:\/\/doi.org\/10.3389\/fneur.2015.00186","journal-title":"Front Neurol"},{"key":"1932_CR299","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3233\/JAD-160366","volume":"55","author":"A Rivero-Santana","year":"2017","unstructured":"Rivero-Santana A, Ferreira D, Perestelo-P\u00e9rez L, Westman E, Wahlund LO, Sarr\u00eda A et al (2017) Cerebrospinal fluid biomarkers for the differential diagnosis between Alzheimer\u2019s disease and frontotemporal lobar degeneration: systematic review, HSROC analysis, and confounding factors. J Alzheimers Dis 55:625\u2013644. https:\/\/doi.org\/10.3233\/JAD-160366","journal-title":"J Alzheimers Dis"},{"key":"1932_CR300","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"J Robinson","year":"2018","unstructured":"Robinson J, Lee E, Xie S, Rennert L, Suh E, Bredenberg C et al (2018) Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141:2181\u20132193. https:\/\/doi.org\/10.1093\/brain\/awy146","journal-title":"Brain"},{"key":"1932_CR301","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","volume":"80","author":"CM Roe","year":"2013","unstructured":"Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D et al (2013) Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5\u00a0years later. Neurology 80:1784\u20131791. https:\/\/doi.org\/10.1212\/WNL.0b013e3182918ca6","journal-title":"Neurology"},{"key":"1932_CR302","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/acn3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V et al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:216\u2013225. https:\/\/doi.org\/10.1002\/acn3.290","journal-title":"Ann Clin Transl Neurol"},{"key":"1932_CR303","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000362164","volume":"4","author":"C Ros\u00e9n","year":"2014","unstructured":"Ros\u00e9n C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L et al (2014) Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Dis Extra 4:297\u2013304. https:\/\/doi.org\/10.1159\/000362164","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"1932_CR304","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jalz.2014.10.013","volume":"11","author":"P Roussos","year":"2015","unstructured":"Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V (2015) The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer\u2019s dementia. Alzheimers Dement 11:1163\u20131170. https:\/\/doi.org\/10.1016\/j.jalz.2014.10.013","journal-title":"Alzheimers Dement"},{"key":"1932_CR305","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ana.24040","volume":"74","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R et al (2013) Predicting Alzheimer disease with \u03b2-amyloid imaging: results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing. Ann Neurol 74:905\u2013913. https:\/\/doi.org\/10.1002\/ana.24040","journal-title":"Ann Neurol"},{"key":"1932_CR306","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JAD-160633","volume":"55","author":"CL Russell","year":"2017","unstructured":"Russell CL, Mitra V, Hansson K, Blennow K, Gobom J, Zetterberg H et al (2017) Comprehensive quantitative profiling of tau and phosphorylated tau peptides in cerebrospinal fluid by mass spectrometry provides new biomarker candidates. J Alzheimers Dis 55:303\u2013313. https:\/\/doi.org\/10.3233\/JAD-160633","journal-title":"J Alzheimers Dis"},{"key":"1932_CR307","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jnc.13932","volume":"140","author":"A Salminen","year":"2017","unstructured":"Salminen A, Kauppinen A, Kaarniranta K (2017) Hypoxia\/ischemia activate processing of amyloid precursor protein: impact of vascular dysfunction in the pathogenesis of Alzheimer\u2019s disease. J Neurochem 140:536\u2013549. https:\/\/doi.org\/10.1111\/jnc.13932","journal-title":"J Neurochem"},{"key":"1932_CR308","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.celrep.2014.02.031","volume":"7","author":"N Salvadores","year":"2014","unstructured":"Salvadores N, Shahnawaz M, Scarpini E, Tagliavini F, Soto C (2014) Detection of misfolded A\u03b2 oligomers for sensitive biochemical diagnosis of Alzheimer\u2019s disease. Cell Rep 7:261\u2013268. https:\/\/doi.org\/10.1016\/j.celrep.2014.02.031","journal-title":"Cell Rep"},{"key":"1932_CR309","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000464422","volume":"24","author":"A Sanabria-Castro","year":"2017","unstructured":"Sanabria-Castro A, Alvarado-Echeverr\u00eda I, Monge-Bonilla C (2017) Molecular pathogenesis of Alzheimer\u2019s disease: an update. Ann Neurosci 24:46\u201354. https:\/\/doi.org\/10.1159\/000464422","journal-title":"Ann Neurosci"},{"key":"1932_CR310","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00702-016-1597-3","volume":"123","author":"C Sanfilippo","year":"2016","unstructured":"Sanfilippo C, Forlenza O, Zetterberg H, Blennow K (2016) Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer\u2019s disease and in mild cognitive impairment due to AD. J Neural Transm (Vienna) 123:1443\u20131447. https:\/\/doi.org\/10.1007\/s00702-016-1597-3","journal-title":"J Neural Transm (Vienna)"},{"key":"1932_CR311","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3233\/jad-142778","volume":"46","author":"MJ Savage","year":"2015","unstructured":"Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ (2015) Soluble BACE-1 activity and sA\u03b2PP\u03b2 concentrations in Alzheimer\u2019s disease and age-matched healthy control cerebrospinal fluid from the Alzheimer\u2019s Disease Neuroimaging Initiative-1 baseline cohort. J Alzheimers Dis 46:431\u2013440. https:\/\/doi.org\/10.3233\/jad-142778","journal-title":"J Alzheimers Dis"},{"key":"1932_CR312","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T et al (2014) A sensitive a\u03b2 oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J Neurosci 34:2884\u20132897. https:\/\/doi.org\/10.1523\/JNEUROSCI.1675-13.2014","journal-title":"J Neurosci"},{"key":"1932_CR313","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.neurobiolaging.2005.09.012","volume":"27","author":"SW Scheff","year":"2006","unstructured":"Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol Aging 27:1372\u20131384. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.09.012","journal-title":"Neurobiol Aging"},{"key":"1932_CR314","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer\u2019s disease. Lancet 388:505\u2013517. https:\/\/doi.org\/10.1016\/s0140-6736(15)01124-1","journal-title":"Lancet"},{"key":"1932_CR315","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med 2:864\u2013870","journal-title":"Nat Med"},{"key":"1932_CR316","first-page":"53","volume":"139","author":"ML Schmidt","year":"1991","unstructured":"Schmidt ML, Murray J, Lee VM, Hill WD, Wertkin A, Trojanowski JQ (1991) Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 139:53\u201365","journal-title":"Am J Pathol"},{"key":"1932_CR317","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R et al (2014) Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J Intern Med 275:251\u2013283. https:\/\/doi.org\/10.1111\/joim.12191","journal-title":"J Intern Med"},{"key":"1932_CR318","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/JAD-151029","volume":"53","author":"J Schuster","year":"2016","unstructured":"Schuster J, Funke SA (2016) Methods for the specific detection and quantitation of amyloid-\u03b2 oligomers in cerebrospinal fluid. J Alzheimers Dis 53:53\u201367. https:\/\/doi.org\/10.3233\/JAD-151029","journal-title":"J Alzheimers Dis"},{"key":"1932_CR319","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JAD-141725","volume":"44","author":"JL Seeburger","year":"2015","unstructured":"Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M et al (2015) Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer\u2019s disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis 44:525\u2013539. https:\/\/doi.org\/10.3233\/JAD-141725","journal-title":"J Alzheimers Dis"},{"key":"1932_CR320","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210","journal-title":"EMBO Mol Med"},{"key":"1932_CR321","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","volume":"6","author":"U Sengupta","year":"2016","unstructured":"Sengupta U, Nilson AN, Kayed R (2016) The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 6:42\u201349. https:\/\/doi.org\/10.1016\/j.ebiom.2016.03.035","journal-title":"EBioMedicine"},{"key":"1932_CR322","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/359325a0","volume":"359","author":"P Seubert","year":"1992","unstructured":"Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D et al (1992) Isolation and quantification of soluble Alzheimer\u2019s \u03b2-peptide from biological fluids. Nature 359:325\u2013327. https:\/\/doi.org\/10.1038\/359325a0","journal-title":"Nature"},{"key":"1932_CR323","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature 537:50\u201356. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"key":"1932_CR324","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/wnl.0000000000003912","volume":"88","author":"P Shahim","year":"2017","unstructured":"Shahim P, Zetterberg H, Tegner Y, Blennow K (2017) Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88:1788\u20131794. https:\/\/doi.org\/10.1212\/wnl.0000000000003912","journal-title":"Neurology"},{"key":"1932_CR325","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C et al (2017) Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 74:163\u2013172. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4547","journal-title":"JAMA Neurol"},{"key":"1932_CR326","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer\u2019s Disease neuroimaging initiative subjects. Ann Neurol 65:403\u2013413. https:\/\/doi.org\/10.1002\/ana.21610","journal-title":"Ann Neurol"},{"key":"1932_CR327","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-011-0808-0","volume":"121","author":"LM Shaw","year":"2011","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K et al (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121:597\u2013609. https:\/\/doi.org\/10.1007\/s00401-011-0808-0","journal-title":"Acta Neuropathol"},{"key":"1932_CR328","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-017-0316-0","volume":"9","author":"KS Sheinerman","year":"2017","unstructured":"Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D et al (2017) Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res Ther 9:89. https:\/\/doi.org\/10.1186\/s13195-017-0316-0","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR329","doi-asserted-by":"publisher","first-page":"e0159099","DOI":"10.1371\/journal.pone.0159099","volume":"11","author":"S Shekhar","year":"2016","unstructured":"Shekhar S, Kumar R, Rai N, Kumar V, Singh K, Upadhyay AD et al (2016) Estimation of tau and phosphorylated tau181 in serum of Alzheimer\u2019s disease and mild cognitive impairment patients. PLoS One 11:e0159099. https:\/\/doi.org\/10.1371\/journal.pone.0159099","journal-title":"PLoS One"},{"key":"1932_CR330","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopsych.2017.02.007","volume":"83","author":"Y Shen","year":"2018","unstructured":"Shen Y, Wang H, Sun Q, Yao H, Keegan AP, Mullan M et al (2018) Increased plasma beta-secretase 1 may predict conversion to Alzheimer\u2019s disease dementia in individuals with mild cognitive impairment. Biol Psychiatry 83:447\u2013455. https:\/\/doi.org\/10.1016\/j.biopsych.2017.02.007","journal-title":"Biol Psychiatry"},{"key":"1932_CR331","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","volume":"480","author":"M Shi","year":"2010","unstructured":"Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D et al (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson\u2019s disease. Neurosci Lett 480:78\u201382. https:\/\/doi.org\/10.1016\/j.neulet.2010.06.009","journal-title":"Neurosci Lett"},{"key":"1932_CR332","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/ng.3916","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J et al (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer\u2019s disease. Nat Genet 49:1373\u20131384. https:\/\/doi.org\/10.1038\/ng.3916","journal-title":"Nat Genet"},{"key":"1932_CR333","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1089\/ars.2012.4931","volume":"20","author":"N Singh","year":"2014","unstructured":"Singh N, Haldar S, Tripathi AK, Horback K, Wong J, Sharma D et al (2014) Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal 20:1324\u20131363. https:\/\/doi.org\/10.1089\/ars.2012.4931","journal-title":"Antioxid Redox Signal"},{"key":"1932_CR334","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jnr.1242","volume":"66","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K et al (2001) Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 66:510\u2013516. https:\/\/doi.org\/10.1002\/jnr.1242","journal-title":"J Neurosci Res"},{"key":"1932_CR335","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/wnl.0000000000001015","volume":"83","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck T, Farahmand B, Bartlett JW, Ros\u00e9n C, Mattsson N, N\u00e4gga K et al (2014) CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83:1945\u20131953. https:\/\/doi.org\/10.1212\/wnl.0000000000001015","journal-title":"Neurology"},{"key":"1932_CR336","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jamaneurol.2013.6455","volume":"71","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck T, Ros\u00e9n C, Asztely F, Mattsson N, Blennow K, Zetterberg H (2014) Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 71:476\u2013483. https:\/\/doi.org\/10.1001\/jamaneurol.2013.6455","journal-title":"JAMA Neurol"},{"key":"1932_CR337","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3233\/JAD-160652","volume":"55","author":"A Slachevsky","year":"2017","unstructured":"Slachevsky A, Guzm\u00e1n-Mart\u00ednez L, Delgado C, Reyes P, Far\u00edas GA, Mu\u00f1oz-Neira C et al (2017) Tau platelets correlate with regional brain atrophy in patients with Alzheimer\u2019s disease. J Alzheimers Dis 55:1595\u20131603. https:\/\/doi.org\/10.3233\/JAD-160652","journal-title":"J Alzheimers Dis"},{"key":"1932_CR338","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3233\/jad-130107","volume":"36","author":"S Slaets","year":"2013","unstructured":"Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP et al (2013) Cerebrospinal fluid A\u03b21-40 improves differential dementia diagnosis in patients with intermediate p-tau181 levels. J Alzheimers Dis 36:759\u2013767. https:\/\/doi.org\/10.3233\/jad-130107","journal-title":"J Alzheimers Dis"},{"key":"1932_CR339","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.jalz.2013.10.004","volume":"10","author":"S Slaets","year":"2014","unstructured":"Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ et al (2014) Increased CSF \u03b1-synuclein levels in Alzheimer\u2019s disease: correlation with tau levels. Alzheimers Dement 10:S290\u2013S298. https:\/\/doi.org\/10.1016\/j.jalz.2013.10.004","journal-title":"Alzheimers Dement"},{"key":"1932_CR340","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jalz.2014.10.008","volume":"11","author":"HM Snyder","year":"2015","unstructured":"Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D et al (2015) Vascular contributions to cognitive impairment and dementia including Alzheimer\u2019s disease. Alzheimers Dement 11:710\u2013717. https:\/\/doi.org\/10.1016\/j.jalz.2014.10.008","journal-title":"Alzheimers Dement"},{"key":"1932_CR341","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1124\/jpet.116.232256","volume":"358","author":"HD Soares","year":"2016","unstructured":"Soares HD, Gasior M, Toyn JH, Wang JS, Hong Q, Berisha F et al (2016) The \u03b3-secretase modulator, BMS-932481, modulates A\u03b2 peptides in the plasma and cerebrospinal fluid of healthy volunteers. J Pharmacol Exp Ther 358:138\u2013150. https:\/\/doi.org\/10.1124\/jpet.116.232256","journal-title":"J Pharmacol Exp Ther"},{"key":"1932_CR342","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fnins.2015.00259","volume":"9","author":"L Steardo Jr","year":"2015","unstructured":"Steardo L Jr, Bronzuoli MR, Iacomino A, Esposito G, Steardo L, Scuderi C (2015) Does neuroinflammation turn on the flame in Alzheimer\u2019s disease? Focus on astrocytes. Front Neurosci 9:259. https:\/\/doi.org\/10.3389\/fnins.2015.00259","journal-title":"Front Neurosci"},{"key":"1932_CR343","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF A\u03b2 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60:652\u2013656","journal-title":"Neurology"},{"key":"1932_CR344","doi-asserted-by":"publisher","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","volume":"8","author":"M Su\u00e1rez-Calvet","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Araque Caballero M\u00c1, Kleinberger G, Bateman RJ, Fagan AM, Morris JC et al (2016) Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8:369ra178. https:\/\/doi.org\/10.1126\/scitranslmed.aag1767","journal-title":"Sci Transl Med"},{"key":"1932_CR345","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/jnnp-2013-305972","volume":"85","author":"M Su\u00e1rez-Calvet","year":"2014","unstructured":"Su\u00e1rez-Calvet M, Dols-Icardo O, Llad\u00f3 A, S\u00e1nchez-Valle R, Hern\u00e1ndez I, Amer G et al (2014) Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J Neurol Neurosurg Psychiatry 85:684\u2013691. https:\/\/doi.org\/10.1136\/jnnp-2013-305972","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1932_CR346","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Su\u00e1rez-Calvet","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Kleinberger G, Araque Caballero M\u00c1, Brendel M, Rominger A, Alcolea D et al (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med 8:466\u2013476. https:\/\/doi.org\/10.15252\/emmm.201506123","journal-title":"EMBO Mol Med"},{"key":"1932_CR347","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","volume":"14","author":"CL Sutphen","year":"2018","unstructured":"Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM et al (2018) Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease. Alzheimers Dement 14:869\u2013879. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.012","journal-title":"Alzheimers Dement"},{"key":"1932_CR348","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.8191290","volume":"264","author":"N Suzuki","year":"1994","unstructured":"Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C et al (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264:1336\u20131340","journal-title":"Science"},{"key":"1932_CR349","first-page":"452","volume":"145","author":"N Suzuki","year":"1994","unstructured":"Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y (1994) High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 145:452\u2013460","journal-title":"Am J Pathol"},{"key":"1932_CR350","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.biopsych.2010.06.012","volume":"68","author":"W Swardfager","year":"2010","unstructured":"Swardfager W, Lanct\u00f4t K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer\u2019s disease. Biol Psychiatry 68:930\u2013941. https:\/\/doi.org\/10.1016\/j.biopsych.2010.06.012","journal-title":"Biol Psychiatry"},{"key":"1932_CR351","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0022-510X(00)00285-9","volume":"175","author":"CI Sze","year":"2000","unstructured":"Sze CI, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ (2000) Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer\u2019s disease brains. J Neurol Sci 175:81\u201390","journal-title":"J Neurol Sci"},{"key":"1932_CR352","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3233\/JAD-161277","volume":"58","author":"YJ Tan","year":"2017","unstructured":"Tan YJ, Ng ASL, Vipin A, Lim JKW, Chander RJ, Ji F et al (2017) Higher peripheral TREM2 mRNA levels relate to cognitive deficits and hippocampal atrophy in Alzheimer\u2019s disease and amnestic mild cognitive impairment. J Alzheimers Dis 58:413\u2013423. https:\/\/doi.org\/10.3233\/JAD-161277","journal-title":"J Alzheimers Dis"},{"key":"1932_CR353","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H et al (2009) Cerebrospinal fluid \u03b2-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66:382\u2013389. https:\/\/doi.org\/10.1001\/archneurol.2008.596","journal-title":"Arch Neurol"},{"key":"1932_CR354","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM et al (2016) Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol 73:561\u2013571. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0086","journal-title":"JAMA Neurol"},{"key":"1932_CR355","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ana.22448","volume":"70","author":"R Tarawneh","year":"2011","unstructured":"Tarawneh R, D\u2019Angelo G, Macy E, Xiong C, Carter D, Cairns NJ et al (2011) Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70:274\u2013285. https:\/\/doi.org\/10.1002\/ana.22448","journal-title":"Ann Neurol"},{"key":"1932_CR356","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/jamaneurol.2015.0202","volume":"72","author":"R Tarawneh","year":"2015","unstructured":"Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH (2015) Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease. JAMA Neurol 72:656\u2013665. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0202","journal-title":"JAMA Neurol"},{"key":"1932_CR357","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1212\/WNL.0b013e318248e568","volume":"78","author":"R Tarawneh","year":"2012","unstructured":"Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78:709\u2013719. https:\/\/doi.org\/10.1212\/WNL.0b013e318248e568","journal-title":"Neurology"},{"key":"1932_CR358","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M et al (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome. Mol Neurodegener 12:63. https:\/\/doi.org\/10.1186\/s13024-017-0206-8","journal-title":"Mol Neurodegener"},{"key":"1932_CR359","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al (1991) Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572\u2013580. https:\/\/doi.org\/10.1002\/ana.410300410","journal-title":"Ann Neurol"},{"key":"1932_CR360","doi-asserted-by":"crossref","unstructured":"The Ronald and Nancy Reagan Research Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group (1998) Consensus report of the working group on: \u201cMolecular and biochemical markers of Alzheimer\u2019s disease\u201d. Neurobiol Aging 19:109\u2013116","DOI":"10.1016\/S0197-4580(98)00022-0"},{"key":"1932_CR361","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","volume":"1362","author":"A Thorsell","year":"2010","unstructured":"Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N et al (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease. Brain Res 1362:13\u201322. https:\/\/doi.org\/10.1016\/j.brainres.2010.09.073","journal-title":"Brain Res"},{"key":"1932_CR362","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3233\/JAD-160829","volume":"56","author":"M Timmers","year":"2017","unstructured":"Timmers M, Bar\u00e3o S, Van Broeck B, Tesseur I, Slemmon J, De Waepenaert K et al (2017) BACE1 dynamics upon inhibition with a BACE inhibitor and correlation to downstream Alzheimer\u2019s disease markers in elderly healthy participants. J Alzheimers Dis 56:1437\u20131449. https:\/\/doi.org\/10.3233\/JAD-160829","journal-title":"J Alzheimers Dis"},{"key":"1932_CR363","unstructured":"Tirucherai G, Ahlijanian M, Crowell J, Kolaitis G, Skudalski S, Medlock M (2016) A single ascending dose study of the tau-directed monoclonal antibody BMS-986168. Abstract presented at the 20th International Congress of Parkinson\u2019s Disease and Movement Disorders. Berlin (19\u201323 June 2016)"},{"key":"1932_CR364","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","volume":"75","author":"T Tokuda","year":"2010","unstructured":"Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T et al (2010) Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766\u20131772. https:\/\/doi.org\/10.1212\/WNL.0b013e3181fd613b","journal-title":"Neurology"},{"key":"1932_CR365","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/brain\/awt188","volume":"136","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M et al (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer\u2019s Coordinating Centre. Brain 136:2697\u20132706. https:\/\/doi.org\/10.1093\/brain\/awt188","journal-title":"Brain"},{"key":"1932_CR366","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J (2013) CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer\u2019s disease. Acta Neuropathol 126:683\u2013697. https:\/\/doi.org\/10.1007\/s00401-013-1148-z","journal-title":"Acta Neuropathol"},{"key":"1932_CR367","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-013-1151-4","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Xie SX, Trojanowski JQ, Shaw LM (2013) Longitudinal change in CSF tau and A\u03b2 biomarkers for up to 48\u00a0months in ADNI. Acta Neuropathol 126:659\u2013670. https:\/\/doi.org\/10.1007\/s00401-013-1151-4","journal-title":"Acta Neuropathol"},{"key":"1932_CR368","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1515\/cclm-2013-0293","volume":"51","author":"J Toombs","year":"2013","unstructured":"Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD et al (2013) Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med 51:2311\u20132317. https:\/\/doi.org\/10.1515\/cclm-2013-0293","journal-title":"Clin Chem Lab Med"},{"key":"1932_CR369","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu S, Okamoto S, Lipton SA, Xu H (2014) Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol Neurodegener 9:48. https:\/\/doi.org\/10.1186\/1750-1326-9-48","journal-title":"Mol Neurodegener"},{"issue":"Suppl 1","key":"1932_CR370","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/jnc.13449","volume":"139","author":"T Tyson","year":"2016","unstructured":"Tyson T, Steiner JA, Brundin P (2016) Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem 139(Suppl 1):275\u2013289. https:\/\/doi.org\/10.1111\/jnc.13449","journal-title":"J Neurochem"},{"key":"1932_CR371","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/cn500101j","volume":"5","author":"KY Tzen","year":"2014","unstructured":"Tzen KY, Yang SY, Chen TF, Cheng TW, Horng HE, Wen HP et al (2014) Plasma A\u03b2 but not tau is related to brain PiB retention in early Alzheimer\u2019s disease. ACS Chem Neurosci 5:830\u2013836. https:\/\/doi.org\/10.1021\/cn500101j","journal-title":"ACS Chem Neurosci"},{"key":"1932_CR372","doi-asserted-by":"publisher","first-page":"35514","DOI":"10.1038\/srep35514","volume":"6","author":"JM Bergen van","year":"2016","unstructured":"van Bergen JM, Li X, Hua J, Schreiner SJ, Steininger SC, Quevenco FC et al (2016) Colocalization of cerebral iron with amyloid beta in mild cognitive impairment. Sci Rep 6:35514. https:\/\/doi.org\/10.1038\/srep35514","journal-title":"Sci Rep"},{"key":"1932_CR373","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","volume":"5","author":"M Oijen van","year":"2006","unstructured":"van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma A\u03b2(1-40) and A\u03b2(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5:655\u2013660. https:\/\/doi.org\/10.1016\/S1474-4422(06)70501-4","journal-title":"Lancet Neurol"},{"key":"1932_CR374","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3233\/JAD-2010-091606","volume":"20","author":"IA Rossum van","year":"2010","unstructured":"van Rossum IA, Vos S, Handels R, Visser PJ (2010) Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 20:881\u2013891. https:\/\/doi.org\/10.3233\/JAD-2010-091606","journal-title":"J Alzheimers Dis"},{"key":"1932_CR375","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","volume":"8","author":"H Vanderstichele","year":"2012","unstructured":"Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL et al (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative. Alzheimers Dement 8:65\u201373. https:\/\/doi.org\/10.1016\/j.jalz.2011.07.004","journal-title":"Alzheimers Dement"},{"key":"1932_CR376","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jnc.12715","volume":"130","author":"R Vassar","year":"2014","unstructured":"Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC et al (2014) Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem 130:4\u201328. https:\/\/doi.org\/10.1111\/jnc.12715","journal-title":"J Neurochem"},{"key":"1932_CR377","doi-asserted-by":"publisher","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM et al (2018) Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.25334","DOI":"10.1002\/ana.25334"},{"key":"1932_CR378","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0306-4522(94)90310-7","volume":"62","author":"JC Vickers","year":"1994","unstructured":"Vickers JC, Riederer BM, Marugg RA, Buee-Scherrer V, Buee L, Delacourte A et al (1994) Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer\u2019s disease. Neuroscience 62:1\u201313","journal-title":"Neuroscience"},{"key":"1932_CR379","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O et al (2013) Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol 12:357\u2013367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70044-9","journal-title":"Lancet Neurol"},{"key":"1932_CR380","doi-asserted-by":"publisher","first-page":"e0151156","DOI":"10.1371\/journal.pone.0151156","volume":"11","author":"G Vivacqua","year":"2016","unstructured":"Vivacqua G, Latorre A, Suppa A, Nardi M, Pietracupa S, Mancinelli R et al (2016) Abnormal salivary total and oligomeric alpha-synuclein in Parkinson\u2019s disease. PLoS One 11:e0151156. https:\/\/doi.org\/10.1371\/journal.pone.0151156","journal-title":"PLoS One"},{"key":"1932_CR381","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-017-0324-0","volume":"9","author":"MJ Wang","year":"2017","unstructured":"Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK et al (2017) Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther 9:98. https:\/\/doi.org\/10.1186\/s13195-017-0324-0","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR382","doi-asserted-by":"publisher","first-page":"121ra120","DOI":"10.1126\/scitranslmed.3002566","volume":"4","author":"Y Wang","year":"2012","unstructured":"Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D et al (2012) Phosphorylated \u03b1-synuclein in Parkinson\u2019s disease. Sci Transl Med 4:121ra120. https:\/\/doi.org\/10.1126\/scitranslmed.3002566","journal-title":"Sci Transl Med"},{"key":"1932_CR383","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/JAD-2012-120253","volume":"32","author":"M Waragai","year":"2012","unstructured":"Waragai M, Yoshida M, Mizoi M, Saiki R, Kashiwagi K, Takagi K et al (2012) Increased protein-conjugated acrolein and amyloid-\u03b240\/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis 32:33\u201341. https:\/\/doi.org\/10.3233\/JAD-2012-120253","journal-title":"J Alzheimers Dis"},{"key":"1932_CR384","doi-asserted-by":"publisher","first-page":"e0135458","DOI":"10.1371\/journal.pone.0135458","volume":"10","author":"M Wennstr\u00f6m","year":"2015","unstructured":"Wennstr\u00f6m M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O et al (2015) The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer\u2019s but not Parkinson\u2019s disease or dementia with Lewy bodies. PLoS One 10:e0135458. https:\/\/doi.org\/10.1371\/journal.pone.0135458","journal-title":"PLoS One"},{"issue":"21","key":"1932_CR385","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"PSJ Weston","year":"2017","unstructured":"Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K et al (2017) Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89(21):2167\u20132175","journal-title":"Neurology"},{"key":"1932_CR386","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jalz.2017.01.010","volume":"13","author":"E Willemse","year":"2017","unstructured":"Willemse E, van Uffelen K, Brix B, Engelborghs S, Vanderstichele H, Teunissen C (2017) How to handle adsorption of cerebrospinal fluid amyloid \u03b2 (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A\u03b242\/A\u03b240 ratio. Alzheimers Dement 13:885\u2013892. https:\/\/doi.org\/10.1016\/j.jalz.2017.01.010","journal-title":"Alzheimers Dement"},{"key":"1932_CR387","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3233\/jad-161116","volume":"58","author":"SM Williams","year":"2017","unstructured":"Williams SM, Schulz P, Rosenberry TL, Caselli RJ, Sierks MR (2017) Blood-based oligomeric and other protein variant biomarkers to facilitate pre-symptomatic diagnosis and staging of Alzheimer\u2019s disease. J Alzheimers Dis 58:23\u201335. https:\/\/doi.org\/10.3233\/jad-161116","journal-title":"J Alzheimers Dis"},{"key":"1932_CR388","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","volume":"101","author":"J Wiltfang","year":"2007","unstructured":"Wiltfang J, Esselmann H, Bibl M, H\u00fcll M, Hampel H, Kessler H et al (2007) Amyloid \u03b2 peptide ratio 42\/40 but not A\u03b242 correlates with phospho-tau in patients with low- and high-CSF A\u03b240 load. J Neurochem 101:1053\u20131059. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04404.x","journal-title":"J Neurochem"},{"key":"1932_CR389","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dadm.2016.04.001","volume":"3","author":"CN Winston","year":"2016","unstructured":"Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D et al (2016) Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst) 3:63\u201372. https:\/\/doi.org\/10.1016\/j.dadm.2016.04.001","journal-title":"Alzheimers Dement (Amst)"},{"key":"1932_CR390","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrn3983","volume":"16","author":"FK Wiseman","year":"2015","unstructured":"Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL et al (2015) A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 16:564\u2013574. https:\/\/doi.org\/10.1038\/nrn3983","journal-title":"Nat Rev Neurosci"},{"key":"1932_CR391","unstructured":"World Health Organization (2017) Dementia factsheet. http:\/\/www.who.int\/mediacentre\/factsheets\/fs362\/en\/ . Accessed August 2017"},{"key":"1932_CR392","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.clinbiochem.2008.04.022","volume":"41","author":"G Wu","year":"2008","unstructured":"Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi XP et al (2008) Decrease in age-adjusted cerebrospinal fluid \u03b2-secretase activity in Alzheimer\u2019s subjects. Clin Biochem 41:986\u2013996. https:\/\/doi.org\/10.1016\/j.clinbiochem.2008.04.022","journal-title":"Clin Biochem"},{"key":"1932_CR393","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/jnr.23122","volume":"90","author":"G Wu","year":"2012","unstructured":"Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X et al (2012) Characterization of plasma \u03b2-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer\u2019s disease. J Neurosci Res 90:2247\u20132258. https:\/\/doi.org\/10.1002\/jnr.23122","journal-title":"J Neurosci Res"},{"key":"1932_CR394","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fnmol.2017.00097","volume":"10","author":"R Yan","year":"2017","unstructured":"Yan R (2017) Physiological functions of the \u03b2-site amyloid precursor protein cleaving enzyme 1 and 2. Front Mol Neurosci 10:97. https:\/\/doi.org\/10.3389\/fnmol.2017.00097","journal-title":"Front Mol Neurosci"},{"key":"1932_CR395","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-170810","volume":"61","author":"CC Yang","year":"2018","unstructured":"Yang CC, Chiu MJ, Chen TF, Chang HL, Liu BH, Yang SY (2018) Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer\u2019s disease. J Alzheimers Dis 61:1323\u20131332. https:\/\/doi.org\/10.3233\/JAD-170810","journal-title":"J Alzheimers Dis"},{"key":"1932_CR396","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-015-0100-y","volume":"7","author":"T Yang","year":"2015","unstructured":"Yang T, O\u2019Malley TT, Kanmert D, Jerecic J, Zieske LR, Zetterberg H et al (2015) A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res Ther 7:14. https:\/\/doi.org\/10.1186\/s13195-015-0100-y","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR397","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC et al (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337\u2013351. https:\/\/doi.org\/10.1016\/j.neuron.2007.01.010","journal-title":"Neuron"},{"key":"1932_CR398","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1242\/jcs.104729","volume":"125","author":"A Yuan","year":"2012","unstructured":"Yuan A, Rao MV, Veeranna Nixon RA (2012) Neurofilaments at a glance. J Cell Sci 125:3257\u20133263. https:\/\/doi.org\/10.1242\/jcs.104729","journal-title":"J Cell Sci"},{"key":"1932_CR399","doi-asserted-by":"publisher","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","volume":"9","author":"A Yuan","year":"2017","unstructured":"Yuan A, Rao MV, Veeranna Nixon RA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 9:a018309. https:\/\/doi.org\/10.1101\/cshperspect.a018309","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1932_CR400","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuron.2016.09.016","volume":"92","author":"P Yuan","year":"2016","unstructured":"Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM et al (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 92:252\u2013264. https:\/\/doi.org\/10.1016\/j.neuron.2016.09.016","journal-title":"Neuron"},{"key":"1932_CR401","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/archneur.65.8.1102","volume":"65","author":"H Zetterberg","year":"2008","unstructured":"Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME et al (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65:1102\u20131107. https:\/\/doi.org\/10.1001\/archneur.65.8.1102","journal-title":"Arch Neurol"},{"key":"1932_CR402","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JAD-2007-12307","volume":"12","author":"H Zetterberg","year":"2007","unstructured":"Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstr\u00f6m C et al (2007) Intra-individual stability of CSF biomarkers for Alzheimer\u2019s disease over two years. J Alzheimers Dis 12:255\u2013260","journal-title":"J Alzheimers Dis"},{"key":"1932_CR403","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM et al (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 73:60\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2015.3037","journal-title":"JAMA Neurol"},{"key":"1932_CR404","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J et al (2013) Plasma tau levels in Alzheimer\u2019s disease. Alzheimers Res Ther 5:9. https:\/\/doi.org\/10.1186\/alzrt163","journal-title":"Alzheimers Res Ther"},{"key":"1932_CR405","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1523\/jneurosci.4922-11.2012","volume":"32","author":"B Zhang","year":"2012","unstructured":"Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS et al (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32:3601\u20133611. https:\/\/doi.org\/10.1523\/jneurosci.4922-11.2012","journal-title":"J Neurosci"},{"key":"1932_CR406","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.toxlet.2016.11.002","volume":"265","author":"QS Zhang","year":"2017","unstructured":"Zhang QS, Heng Y, Yuan YH, Chen NH (2017) Pathological \u03b1-synuclein exacerbates the progression of Parkinson\u2019s disease through microglial activation. Toxicol Lett 265:30\u201337. https:\/\/doi.org\/10.1016\/j.toxlet.2016.11.002","journal-title":"Toxicol Lett"},{"key":"1932_CR407","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/archpsyc.64.6.718","volume":"64","author":"Z Zhong","year":"2007","unstructured":"Zhong Z, Ewers M, Teipel S, B\u00fcrger K, Wallin A, Blennow K et al (2007) Levels of \u03b2-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64:718\u2013726. https:\/\/doi.org\/10.1001\/archpsyc.64.6.718","journal-title":"Arch Gen Psychiatry"},{"key":"1932_CR408","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2017.04.027","volume":"650","author":"W Zhou","year":"2017","unstructured":"Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y et al (2017) Plasma neurofilament light chain levels in Alzheimer\u2019s disease. Neurosci Lett 650:60\u201364. https:\/\/doi.org\/10.1016\/j.neulet.2017.04.027","journal-title":"Neurosci Lett"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-018-1932-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-018-1932-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-018-1932-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T20:37:38Z","timestamp":1662496658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-018-1932-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":408,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1932"],"URL":"https:\/\/doi.org\/10.1007\/s00401-018-1932-x","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JLM is Principal Investigator of trials funded by Roche, Merck, Novartis, and Janssen and has received speaker or consultant fees from Roche, Roche Diagnostics, Biogen, Merck, Novartis, Oryzon, IBL, Axovant, Lundbeck, and Lilly. SA receives current research support from the National Health and Medical Research Council, Australia (GNT1147442, GNT1123625, GNT1124356, GNT1100441, GNT1101533, GNT1100458) and several non-profit organizations. SA is a co-inventor on biomarker patents related to ferritin. RB is a full-time employee of Roche Diagnostics International. MMB is a full-time employee of Takeda Pharmaceuticals International Co. TB is a full-time employee of Genentech, a member of the Roche Group. JC has provided consultation to Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Avanir, Axovant, Axsome, BiOasis Technologies, Biogen, Boehinger-Ingelheim, Eisai, Genentech, Grifols, Kyowa, Lilly, Lundbeck, Merck, Nutricia, Otsuka, QR Pharma, Resverlogix, Roche, Samus, Servier, Suven, Takeda, Toyoma, and United Neuroscience companies. JC receives support from Keep Memory Alize (KMA), COBRE grant #P20GM109025; TRC-PAD #R01AG053798; DIAGNOSE CTE #U01NS093334. AMF has served as a consultant or on advisory boards for AbbVie, Araclon\/Grifols, DiamiR LLC, Eli Lilly, Genentech, IBL International, and Roche Diagnostics, and has received research support from Biogen, Fujirebio, and Roche Diagnostics. HH serves as Senior Associate Editor for the Journal Alzheimer\u2019s and Dementia; he received lecture fees from Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to the institution), travel funding from Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE-Healthcare and Oryzon Genomics, consultancy fees from Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare Oryzon Genomics, and Functional Neuromodulation, and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics. HH is co-inventor in the following patents as a scientific expert and has received no royalties: (1) In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388. (2) In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784. (3) Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300. (4) In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463. (5) In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286. (6) In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822. (7) In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number: 7547553. (8) CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797. (9) In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number: 20080199966. (10) Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20080131921. MMM served as a consultant to Eli Lilly and Lysosomal Therapeutics, Inc., and receives research support from the National Institutes of Health (R01 AG49704, P50 AG44170, U01 AG06786 RF1 AG55151), Department of Defense (W81XWH-15-1), and unrestricted research grants from Biogen, Roche, and Lundbeck. AM was an employee of Biogen when this manuscript was started. SO has served as a consultant to Roche Diagnostics and has multiple patents on blood biomarkers related to neurodegenerative disease. He is a founder of Cx Precision Medicine and owns stock. He receives research support for the NIH (R01AG058252, R01AG051848, R01AG054073) and the opinions discussed here do not reflect those of the NIA. PS has acquired grant support (for the institution) from Danone Research, Piramal and Merck. In the past 2\u00a0years he has received consultancy\/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Sanofi, Probiodrug, Biogen, Roche and EIP Pharma. JS was an employee of Roche when this manuscript was started. LMS receives research support from the National Institutes of Health (U19 AG024904, P30 AG-10124 for Biomarker Core), Eli Lilly, Hoffman LaRoche, MJFox Foundation for Parkinson\u2019s Research for Biofind study and has served as consultant and\/or advisory boards for Roche Diagnostics and Eli Lilly. HS is a full-time employee of AbbVie Inc. GT is a full-time employee of Lundbeck Pharmaceuticals LLC. JQT receives research support from the National Institutes of Health (P30 AG-10124-27, P01 AG-17586-18 and P50 NS-053488-11), Eli Lilly, Janssen, Biogen, and several non-profit organizations. JQT has received revenue from the sale of Avid to Eli Lily as co-inventor on imaging related patents submitted by the University of Pennsylvania, and may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is co-Inventor. HZ has served at advisory boards for Roche Diagnostics and Eli Lilly and has received travel support from Teva. KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}